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Abstract 
Background During the past 23 years the incidence of tickborne rickettsioses increased 
in Kazakhstan but studies on epidemiological data, vector species, 
prevalence and distribution are still insufficient to date. Unfortunately most 
cases of rickettsioses are remained unconfirmed due to the lack of modern 
diagnostic tests. The purpose of the research was molecular investigation 
of ticks for spotted-fever group rickettsiae in two pilot regions of 
Kazakhstan and to detect its role as a cause of the fever of unknown origin 
(FUO). 
Methods Six different tick species were collected and sorted from two selected 
regions in Kazakhstan. DNA was isolated and all tick samples were 
investigated for the presence of Rickettsia by real-time PCR. Multi-locus 
sequence typing (MLST) was conducted for positive samples. Serological 
study on the presence of antibodies against Rickettsia was performed at 
the same regions with serum samples from 802 patients with FUO. 
Statistical analyses were done with R. 
Results Rickettsial minimum infection rate in collected ticks varied within 0.4–
15.1% in Almaty region and 12.6–22.7% in Kyzylorda region. Four 
different Rickettsia species were identified. Two of them are already 
known: Rickettsia raoultii and R. slovaca, the latter was detected for the 
first time in Almaty region. And two new – “Candidatus R. 
yenbekshikazakhensis” and “genotype R.talgarensis” – were identified by 
MLST. In the serological study, 11 (1.4%) patients with acute tick-borne 
rickettsiosis and 22 (2.7%) patients with acute typhus rickettsiosis were 
detected. 
Conclusion Kazakh clinicians should be aware of Rickettsia spp. circulating in both 
investigated regions. R. raoultii and R. slovaca, which are human 
pathogenic, should be included in the diagnostics. The human 
pathogenicity of the two newly described rickettsiae has to be further 
investigated. Further rickettsioses can be a cause of FUO, which has to be 
taken into account for diagnostics. 
 
 
 
v 
 
Declaration of Published Contents 
Parts of this thesis have been published in the peer-reviewed paper 
Turebekov N., Yegemberiyeva R., Dmitrowsky, A., Yeralieyeva L., Shapieyeva Z., 
Abdiyeva K., Amirbekov A., Oradova A., Kachiyeva S., Ziyadina L., Hölscher M., 
Fröschl G., Dobler G., Zinner J., Frey S., Essbauer S., 2019: Prevalence of Rickettsia 
species in ticks including identification of unknown species in two regions in 
Kazakhstan. Parasites and Vectors (in press). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Content 
Key words ....................................................................................................................... iii 
Abstract .......................................................................................................................... iv 
Declaration of Published Contents .................................................................................. v 
List of Tables ................................................................................................................ viii 
List of Figures ................................................................................................................. ix 
List of Abbreviations ........................................................................................................ x 
1. Introduction................................................................................................................. 1 
1.1. Overview on the spotted fever group of Rickettsia ............................................... 1 
1.1.1 Spotted fever group of Rickettsia in Kazakhstan .......................................... 3 
1.2 Rickettsia as a causative agent of the fever of unknown origin ............................ 5 
2. Rationale and Objectives ........................................................................................... 8 
3.   Methods .................................................................................................................... 9 
3.1. Tick sampling ...................................................................................................... 9 
3.2 Tick sample preparation and DNA isolation from ticks ....................................... 10 
3.3 Screening PCR and rickettsial species identification by multi locus sequence 
typing (MLST) ........................................................................................................... 10 
3.4 Description of variables in questionnaires .......................................................... 13 
3.5 Serum sampling ................................................................................................. 17 
3.6 Serological investigations by Rickettsia typhi and Rickettsia spotted fever group 
ELISA ....................................................................................................................... 17 
3.7 Statistical analysis .............................................................................................. 18 
4. Results...................................................................................................................... 19 
4.1. Results of the tick study..................................................................................... 19 
4.2. Results of the serological study. ........................................................................ 32 
5. Discussion ................................................................................................................ 42 
5.1. Discussion of tick study ..................................................................................... 42 
5.1. Discussion of serological study ......................................................................... 44 
6. Conclusion................................................................................................................ 45 
6.1 Conclusion ......................................................................................................... 45 
6.2 Recommendations ............................................................................................. 46 
7. References ............................................................................................................... 47 
8. Annex ....................................................................................................................... 52 
vii 
 
Curriculum vitae ....................................................................................................... 52 
List of publications in International peer-reviewed journals ...................................... 53 
Statement on Pre-release and Contribution ............................................................. 54 
Acknowledgements .................................................................................................. 55 
Affidavit ......................................................................................................................56 
Informed Consent Form ........................................................................................... 57 
Questionnaire ........................................................................................................... 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
List of Tables 
  Page 
Table 1.1: Modern classification of Rickettsia. 2 
Table 3.1: Overview on used primers and PCRs. 11 
Table 4.1: Overview on collected tick species originating from two regions in 
Kazakhstan. 
 
20 
Table 4.2: Distribution of Rickettsial DNA in the collected tick species. 21 
Table 4.3: Distribution of Rickettsial DNA in the collecting localities. 22 
Table 4.4: Distribution of detected Rickettsia species in the tick species 23 
Table 4.5: Distribution of Rickettsia species by collecting localities. 23 
Table 4.6: Sequences with 100% homology to known Rickettsia species. 24 
Table 4.7: Overview of closest nucleotide identities of Candidatus species to the 
first hit in BLAST Rickettsia species. 
 
25 
Table 4.8: Prevalence of IgG antibodies against spotted fever group of 
Rickettsia in patients presenting with fever of unknown origin in two 
regions of Kazakhstan (2015-2016). 
 
 
32 
Table 4.9: Results of ELISA IgG titers against spotted fever group of Rickettsia. 33 
Table 4.10: Patients with acute infection of the spotted fever group of Rickettsia. 33 
Table 4.11: Prevalence of IgM and IgG antibodies against typhus group of 
Rickettsia in patients presenting with fever of unknown origin in two 
regions of Kazakhstan (2015-2016). 
 
 
34 
Table 4.12: Results of ELISA IgG titers against typhus group of Rickettsia. 35 
Table 4.13: Patients with acute infection of the typhus group of Rickettsia. 35 
Table 4.14: Revealed features of inpatients with acute infection of the spotted 
fever group of rickettsia in two regions of Kazakhstan (2015 – 2016). 
 
37 
Table 4.15: Clinical manifestations in patients with acute infection of the spotted 
fever group of rickettsia. 
 
39 
Table 4.16: Revealed features of inpatients with acute infection of the typhus 
group of Rickettsia in two regions of Kazakhstan (2015 – 2016). 
 
40 
Table 4.17: Clinical manifestations in patients with acute infection of the typhus 
group of Rickettsia. 
 
41 
 
 
ix 
 
List of Figures 
  Page 
Figure 1.1: Taxonomy of Rickettsia. 2 
Figure 1.2: Localization of tick-borne rickettsioses in Kazakhstan. 4 
Figure 1.3: Incidence of tick-borne rickettsiosis in Kazakhstan based on 
complement fixation test. 
 
4 
Figure 4.1: Kazakhstan, the two study regions and distribution of the tick species 
found at the sampling sites. 
 
19 
Figure 4.2: Kazakhstan, the two study regions and distribution of the detected 
Rickettsia species found at the sampling sites. 
 
21 
Figure 4.3: Maximum Likelihood phylogenetic tree based on 226 partial ompB 
DNA sequences. 
 
26 
Figure 4.4: Maximum Likelihood phylogenetic tree based on 62 partial ompAIV 
sequences. 
 
27 
Figure 4.5: Maximum Likelihood phylogenetic tree based on 40 partial 23S-5S 
sequences. 
 
28 
Figure 4.6: Maximum Likelihood phylogenetic tree based on partial 27 partial 
16S sequences. 
 
29 
Figure 4.7: Maximum Likelihood phylogenetic tree based on 57 partial sca4 
sequences. 
 
30 
Figure 4.8: Maximum Likelihood phylogenetic tree based on partial 55 partial gltA 
sequences. 
 
31 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Abbreviations 
CFT Complement fixation test 
CI Confidence interval 
DEBONEL Dermacentor-borne necrosis erythema and lymphadenopathy 
DNA Deoxyribonucleic acid  
dNTP Deoxynucleoside triphosphate 
ELISA Enzyme-linked immunosorbent assay  
FUO Fever of unknown origin 
gltA Citrate synthase gene 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
MIR Minimum infection rate 
MLST Multi-locus sequence typing 
ompAIV Outer membrane protein A IV 
ompB Outer membrane protein B 
OR Odds Ratio  
OR a Adjusted Odds Ratio 
PCR Polymerase chain reaction 
RNA Ribonucleic acid  
rt-PCR Real time polymerase chain reaction 
sca4 Cell surface antigen 4 gene 
SENLAT Scalp eschar with neck lymphadenopathy 
SFG Spotted fever group 
SOP Standard operating procedure 
TG Typhus group 
TIBOLA Tick-borne lymphadenopathy 
UDG Uracil-DNA-glycosylase 
 
 
 
1 
 
1. Introduction 
1.1. Overview on the spotted fever group of Rickettsia 
 This research work has been devoted to the investigation of rickettsial bacterial 
agent that causes various types of spotted fevers and typhoid fever around the world (1, 
2). 
 Rickettsia are small (0.3 µm – 1.0 µm), aerobic, motionless, non-spore formed, 
gram-negative, arthropod-associated microorganism with obligate intracellular life 
cycles in eukaryotic cells, such as endothelial cells. Rickettsia species are pleomorphic 
bacterial agents, which can mostly form cocci and bacilli. This microorganism has the 
characters of bacteria and viruses at the same time. As a bacterium, Rickettsia has own 
cell membrane, both nucleic acids (DNA and RNA) and multiply by binary fission in the 
cytosol. In comparison to viruses, Rickettsia are intracellular parasite with several 
species causing cell death and can be cultivated only by using cell cultures or eggs 
cultures (3).  
 Historically, this rickettsiae were discovered more than 100 years ago, by the 
American pathologist and microbiologist Howard Taylor Ricketts (1871 – 1910). He 
dedicated the last decade of his life for investigation of the causative agents and mode 
of transmission of Rocky Mountain spotted fever (USA) and epidemic typhus in Mexico 
City (Mexico), where he died. He discovered that Rickettsiae are arthropod-borne 
microorganisms, which can be found in ticks, lice, fleas. Later, in memory of H.T. 
Ricketts, the genus Rickettsia was named behalf his name (4).  
 During the past three decades, due to the implementation of the molecular 
biological methods and new identification techniques, such as multi-locus sequence 
typing (MLST) or next generation sequencing, the Rickettsia taxonomy was revised 
(5,6).  For details of the general taxonomy of rickettsia see figure 1.1 on the next page. 
At the present time, the genus Rickettsia is represented with 32 officially recognized 
and validated species, which are spread all over the world, excluding Antarctica. Almost 
half of them are identified and confirmed as human pathogens, which can cause 
various diseases from subclinical to severe forms. The pathogenicity of others rickettsial 
agents so far is not yet detected. As arthropod-borne bacterial organisms, Rickettsia 
species are mostly transmitted by Ixodid ticks, lice, fleas or mites, which can be not only 
the vectors but also their reservoirs for Rickettsia (2). 
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Domain:                                                       Bacteria 
Philum:                                                    Proteobacteria 
Class:                                                  Alphaproteobacteria 
Order:                                                         Rickettsiales 
Family:   Rickettsiaceae          Anaplasmataceae          Holosporaceae          unassigned 
Genus: Rickettsia  Occidentia  Orientia 
Figure 1.1 Taxonomy of Rickettsia. 
 According to the newest scientific classification (2018), all Rickettsia spp. are 
divided into two major groups: spotted fever group of Rickettsia and typhus group of 
Rickettsia (Table 1.1) (7). 
Table 1.1 Modern classification of Rickettsia. 
Spotted fever group of Rickettsia Typhus group of Rickettsia 
Spotted fever group Typhus group 
R. rickettsia subgroup “Ancestral” group 
R. conorii subgroup R. bellii subgroup 
R. australis subgroup R. canadensis subgroup 
R. felis group  
R. akari group  
  
During the last decades, the knowledge for the spotted group of rickettsiae and 
its significance of inducing human diseases has been considerably enhanced. The new 
innovation molecular techniques, such as multi-locus sequence typing lead to the 
description of several new Rickettsia Candidatus species by describing at least four or 
five gene fragments or new Rickettsia genotypes if less than four sequences are 
characterized (2, 8-10). 
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1.1.1 Spotted fever group of Rickettsia in Kazakhstan 
In Kazakhstan the clinical picture of human cases of tick-born rickettsiosis were 
first described during expeditions to Almaty region already in 1949 to 1951 (11). A few 
years later clinical pictures of tick-borne rickettsiosis were described further in five 
districts i.e. South Kazakhstan, West Kazakhstan, Pavlodar, North Kazakhstan and 
Akmola regions (12). The causative agent of North Asian tick-borne rickettsiosis (R. 
sibirica) was first described and isolated in 1961 by intra-abdominal infection of guinea 
pig males with homogenates containing Dermacentor marginatus and Haemaphysalis 
punctata ticks, which were collected in Yenbekshikazakh district of Almaty region (13). 
Since only 1995 there exits registration of tick-borne rickettsioses cases in 
humans. According this a clinical case definition criterion and a complement fixation test 
(CFT) with R. sibirica are used in Kazakhstan for diagnostics and thus for registration. 
So far for four regions in Kazakhstan four regions are currently considered as endemic 
regions for tick-borne rickettsioses, which are North Kazakhstan, Pavlodar, East 
Kazakhstan and Kyzylorda (Fig. 1.2).  
So, case numbers are registered in these four regions. According to these 
available reports, in total 3.904 human cases of tick-borne rickettsiosis were officially 
registered in Kazakhstan from 1995 to 2016. During this time the incidence rate of this 
disease rise from 0.41 to 1.19 (per 100,000 inhabitants per year). The highest increase 
was found during this period in Kyzylorda (1.64 – 11.1 per 100,000 inhabitants per year) 
and Pavlodar (1.07 – 7.0 per 100,000 inhabitants per year) regions. Annual 
development of incidence is shown in Figure 1.3. With the present available data, the 
Kyzylorda region is presumed to be the most endemic area for tick-borne rickettsioses 
in Kazakhstan (14). 
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Figure 1.2 Localization of tick-borne rickettsioses in Kazakhstan. 
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Figure 1.3 Incidence of tick-borne rickettsiosis in Kazakhstan based on 
complement fixation test. Source: Annual report: Epidemiological situation of 
infectious diseases in the Republic of Kazakhstan for 2018 (14). 
So far, we can only find limited data on Rickettsia species that might be present 
in the endemic regions of Kazakhstan. R. raoultii was found in Dermacentor spp. and 
Ixodes spp. in three regions Kyzylorda, Karaganda, and East Kazakhstan, Kazakhstan 
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(15 –20). Further, R. conorii subsp. caspia, R. raoultii and R. aeschlimannii were 
described in ticks originating from Western, Northern and Central regions of 
Kazakhstan (21). R. aeschlimannii was detected in Haemaphysalis punctata in Almaty 
region (17, 18). Recently, American colleagues described R.conorii subsp. caspia in 
ticks taking a blood meal on four-striped grass rats (Rhabdomys pumilio) originating 
from the West Kazakhstan region. In 2017 Rickettsia asembonensis and Rickettsia 
felis/Candidatus Rickettsia senegalensi were described in fleas sampled in Almaty 
region (12, 22, 23).  
All these hints from references show that there is a quite limited knowledge on 
Rickettsia spp. from the spotted fever group circulating in the Almaty region which is the 
most densely populated region in Kazakhstan. Despite some old data Almaty region is 
not named as an endemic region and therefore there are no registered epidemiological 
data on human infections from Almaty region (24). Therefore, presently there are still 
big gaps regarding the knowledge on circulating Rickettsia species in ticks and their 
geographical distribution in Kazakhstan. This research work present data of a study of 
molecular investigation of ticks for SFG of Rickettsia in the Almaty region, which is 
considered so far non-endemic, and in the endemic Kyzylorda region. 
 
1.2 Rickettsia as a causative agent of the fever of unknown origin 
Despite the advances achieved in diagnosis and treatment in recent decades, 
fever of unknown origin (FUO) still remains a challenging clinical problem all over the 
world, especially in developing countries. For the first time, the concept of fever of 
unknown origin was defined by R.G. Petersdorf and P.B. Beeson in 1961 which has not 
changed over the next 30 years (25). After this time, in 1991 it was suggested to 
classify FUO into four types (classical, nosocomial, neutropenic and HIV-associated 
FUO) and proposed to reduce the duration of the human diagnostic evaluation from one 
week to three outpatient visits or three days inpatient examination (26). 
To date, there are more than 200 diseases that are accompanied by fever of 
unknown origin (27). In Kazakhstan, so far, no study on patients with fever of unknown 
origin was conducted. Herein, I have focused on investigating antibodies against the 
group of the wide spread intracellular bacteriae from the genus Rickettsia in patients 
having FUO. 
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Rickettsia of the typhus group are R. prowazekii, which is transmitted by the 
human body louse, and is a causative agent of epidemic typhus (louse-borne typhus). 
Outbreaks of louse-borne typhus often occur among the representatives of the poor 
strata of the population during the cold seasons (28). According to WHO, the recent 
outbreaks of typhus fever have been reported in central and eastern Africa (Burundi, 
Ethiopia, Rwanda), central and South America, and Asia (29). Further, R. typhi is a 
member of the typhus group (TGR, typhus group of Rickettsia) transmitted by fleas and 
causes murine typhus (endemic typhus, flea-borne typhus). Mostly, the persons who 
come into contact with flea-infested domestic and wild animals (rodents) are at high risk 
for endemic typhus (28). Flea-borne typhus is widely distributed around the world, 
mainly in rat-infected tropical and subtropical areas (30). 
Rickettsiae of the spotted fever group (SFG, spotted fever group) are pathogens 
which induce a number of tick-transmitted rickettsioses including Rocky Mountain 
spotted fever, Mediterranean spotted fever, Far Eastern spotted fever, North Asian tick 
typhus, Astrakhan spotted fever etc (28). Tick-borne rickettsioses are distinguished by 
its natural focality and endemicity, which is often reflected in the name of a rickettsiosis.  
Many types of rickettsial diseases (louse-, fleas-, tick-bite) are characterized by 
similar general symptoms such as developing within 1 – 2 weeks of infection and 
including fever, headache, malaise, rash (maculopapular, vesicular, or petechial), 
nausea, and vomiting (28). In this regard, the clinical diagnosis of rickettsiosis presents 
certain difficulties for practitioners. Some tick-bite rickettsioses are characterized by 
certain typical signs that facilitate the diagnosis by clinicians in this group of patients 
(28-33). For to date, it is well-known that R. slovaca and R. raoultii are the causative 
agents of tick-borne lymphadenopathy (TIBOLA) syndrome which is also named as 
Dermacentor-borne necrosis erythema and lymphadenopathy (DEBONEL) and 
common in Southern and Eastern Europe and Asia (28). The main symptoms of this 
disease are asthenia (in 70 – 100% cases), painful lymphadenopathies (in 69 – 100% 
cases), painful eschar (in 64 – 100% cases) and fever (in 54 – 80% cases) (31). In 
publications, this syndrome is also called as scalp eschar with neck lymphadenopathy 
(SENLAT) and recently, it became known that one more rickettsial pathogen (R. 
massiliae) is responsible for the onset of this disease (32, 33). 
The data concerning the circulating tick-borne Rickettsia species in Kazakhstan 
were described above. 
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As for epidemic and murine typhus, there is no official registration and no reliable 
diagnostic tests available in Kazakhstan. Mostly, Kazakh practitioners diagnose typhus 
based on epidemiological data and typical patient clinical pattern.  
Until now, so far in Kazakhstan no large-scale serological study for the 
prevalence of antibodies against rickettsia has been conducted. 
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2. Rationale and Objectives 
 Despite the existence of recognized endemic areas in Kazakhstan, the annual 
cases of tick-associated rickettsiosis are unknown especially in the non-endemic 
regions of the country. So far there is lack of data concerning on the prevalence of 
selected agent in vectors such as ticks in natural foci and on serological prevalence of 
antibodies against spotted fever group of Rickettsia in the Republic of Kazakhstan. 
 The above-mentioned challenges have led us to highlight the following research 
objectives: 
1. Look at the prevalence of selected bacterial agent (Rickettsia) in ticks 
collected from two selected regions of Kazakhstan 
2. Explore the serological prevalence of antibodies against tick-transmitted 
Rickettsia in two selected regions  
3. Molecular genetic characterization of the circulating species of Rickettsia. 
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3.   Methods 
3.1. Tick sampling 
Ticks were collected by flagging, i.e. drawing a 1 m3 sheet along, the vegetation 
in three districts of Almaty region (Talgar, Yeskeldy and Yenbekshikazakh districts) and 
Kyzylorda region (Syrdarya, Shyeli and Zhanakorgan districts), Kazakhstan, in 
May/June 2015.  
In Almaty region three sample sites were chosen and ticks were collected there:  
(i) Yeskeldy district (44°54′12″N, 78°29′42″E) with Tekeli city (44°49′48″N, 78°49′26″E) 
is located in Almaty region adjacent to the People's Republic of China and is 
characterized by coniferous forests and open steppe vegetation. The region is situated 
mountaineous at an altitude of 1400–2200 m above sea level (asl). More than 40% of 
the area is covered by forest, and the remaining parts constitute of pasture and 
agricultural land. Animal husbandry is practiced widely. The average annual 
precipitation has been reported as 250–300 mm (34). (ii)Talgar district (43°18′55″N, 
77°14′35″E) with Talgar city (43°18′0″N, 77°14′0″E) is 40 km away from Almaty city 
center and comprises of forested taiga, forested steppe, and arid fields, the latter mainly 
covered by gramineous plants. Nearly 20% of its northern part is elevated at 1800 to 
2400 m asl and is therefore mountaineous. The annual precipitation is 200–300 mm 
(34). (iii) Yenbekshikazakh district (43°21′0″N, 77°28′0″E) with Yesyk city (43°21′0″N, 
77°28′0″E) offers areas of maritime climate in summer and very cold temperatures 
(from -25°C down to -50°C) during winter. Average precipitation is reported as 200–700 
mm/year. Plain steppe and meadows dominate most parts of this area (34). 
In the Kyzylorda region ticks were collected in three districts:  
Syrdarya (45°34′12″N, 65°36′0″E), Shyeli (44°10′0″N, 66°44′0″E) and Zhanakorgan 
(43°56′24″N, 67°13′12″E) districts. Kyzylorda region (45°0’0’’N, 64°0’0’’E) is located in 
the south-western part of Kazakhstan, to the east of the Aral Sea in the lower reaches 
of the Syrdarya river, mainly within the Turan Lowland (altitude 50-200 m above sea 
level). The region borders the neighboring country Uzbekistan, as well as three other 
Kazakh regions: Aktobe region (to the west), Karaganda region (to the north), 
and South Kazakhstan (to the east). The climate is rather continental and extremely 
arid with prolonged hot and dry summers and with a comparatively warm, short and 
little snowy winter. The amount of precipitation in the north-west near the Aral Sea 
coast is about 100 mm (the lowest in Kazakhstan), in the southeast in the foothills of 
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Karatau mountain is up to 175 mm. A significant part of the region is occupied by 
sands, almost devoid of vegetation (35). 
 
3.2 Tick sample preparation and DNA isolation from ticks 
Ticks, collected by flagging in the field, were brought to the laboratory and stored 
at −20°C until further investigation. The laboratory investigation was performed in 
batches. After thawing, all field ticks have been sorted according genus, species, stage 
and sex following the official guidelines for tick specification in Kazakhstan (36-39). 
Later the ticks were grouped into pools by genus, species, stage and sex (with a 
maximum of 5 imago ticks in a pool). Each pool has been homogenized using the 
“Tissue Lyser II” instrument machine, after adding ceramic granules and 1 ml medium 
“DMEM” (BioloT, Saint-Petersburg, Russia) to each tube. Following Kazakh guidelines 
for biosafety and biosecurity aliquots containing tick homogenates were inactivated in 
the water bath at 56C for 30 min, before DNA extraction. DNA was extracted from 200 
l tick homogenates using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), 
according to the manufacturer’s instructions. The final elution volume was 50 µl DNA. 
 
3.3 Screening PCR and rickettsial species identification by multi locus 
sequence typing (MLST) 
All PCRs were conducted in a three-room-regime following the one-way-
principle.  
In a first step for all samples the presence of rickettsial DNA was determined by 
a real-time PCR assay targeting the pan-rickettsial citrate synthase gene (primers and 
probe see Table 3.1) using Uracil–DNA–glycosylase (UDG) in order to eliminate carry-
over contamination (40, 41) in a “Rotor-Gene Q” (Qiagen) machine.  
In all samples yielding a positive pan-rickettsial citrate synthase gene signal, a 
multi-locus sequence typing (MLST) targeting six gene fragments (partial fragments 
of ompB, ompAIV, 23S-5S interspacer, 16S, sca4, gltA) was conducted for 
Rickettsia species identification (40-43). Firstly, for all these samples the partial outer 
membrane protein B (ompB) gene (RR 120-2788, cRR 120-3599) was amplified 
following published protocols (43). Secondly, for the samples with positive sequences 
(depending on the sequence result) five additional fragments were investigated 
using previously published primers (42, 40–47): ompAIV (RR 190-5125, cRR 190-
11 
 
6013), 23S-5S interspacer (23s for, 23s rev), 16S (Ric, Ric RT), sca4 (Rsca4_1707f, 
Rsca4_2837r) and partial gltA (Rh314, Rh654) (Table 3.1) (40-43).  
Table 3.1 summarizes an overview of all PCR primers used in the tests.  
Table 3.1 Overview on used primers and PCRs 
Fragment 
 
Forward primer 
 
Reverse primer 
 
Length 
(bp) 
Ref. 
 
gltA* 
PanRick_gltA_2_for: 
5'-ATAGGACAACCGTTTATTT-3' 
PanRick_gltA_2_rev: 
5'-CAAACATCATATGCAGAAA-3' 
90 
41, 
42
 
ompB 
RR 120-2788: 
5’-AAACAATAATCAAGGTACTGT-3' 
cRR 120-3599 
5’-TACTTCCGGTTACAGCAAAGT-3' 
811 44 
ompAIV 
RR 190-5125: 
5’-GCGGTTACTTTAGCCAAAGG-3' 
cRR 190-6013: 
5’-TCTTCTGCGTTGCATTACCG-3' 
888 43 
23S 
Rick 23s for: 
5´-gATAggTCgggTgTggAAgCAC-3’ 
Rick 23s rev: 
5´-gggATgggATCgTgTgTTTCAC-3’ 
378 – 532 
45, 
this 
study
 
16S 
Ric: 
5´-TCTAGAACGAACGCTATCGGTAT-3' 
RicRt: 
5'-TTTCATCGTTTAACGGCGTGGACT-3' 
752 46 
sca4 
Rsca4_1707f: 
5’-CTCTgAATTAAgCAATgCgg-3' 
Rsca4_2837r: 
5’-CCTgATACTACCCTTACATC-3' 
1130 47 
gltA 
RH314: 
5'-AAACAGGTTGCTCATCATTC-3' 
RH654: 
5'-AGAGCATTTTTTATTATTGG-3' 
340 48 
* real-time PCR, probe. PanRick_gltA_2_taq: 5’-6FAM-CCTGATAATTCGTTAGATTTTACCG-DB-3’ 
Ref. – reference, bp – base pairs 
Master mix solution for 23S-5S interspacer PCR (50 µl including 5 µl DNA) 
were prepared with 0.2 mM dNTP Mix (Thermofisher-Invitrogen, Schwerte, 
Germany), 0.5 µM of each primer (23s for, 23s rev), 1.5 U Platinum® Taq DNA 
Polymerase High Fidelity (Thermofisher-Invitrogen), 1x PCR buffer (Thermofisher) 
and 2.0 mM MgSO4 (Thermofisher). The initial denaturation was performed for 3 
min at 95°C, 45 cycles of amplification each started with denaturation for 20 sec. at 
95°C, annealing for 30 sec. at 57°C and elongation at 68°C for 60 sec. The 
amplification ended with a final elongation for 10 min at 68°C (44, 48).  
Gene D (sca4) sequences were amplified with 0.2 mM dNTP Mix 
(Thermofisher- Invitrogen), 0.1µM of each primer (Rsca4_1707f, Rsca4_2837r), 1.0 
U Platinum® Taq DNA Polymerase High Fidelity (Thermofisher-Invitrogen), 1x PCR 
buffer, 3 mM MgSO4 and 2µl DNA in a final volume of 50 µl for each reaction. After 
an initial denaturation for 3 min at 95°C, 40 cycles with denaturation for 30 sec. at 
95°C, annealing for 35 sec at 53°C and elongation for 90 amplification ended with a 
final extension for 7 min at 68°C. The runs were finished with a final elongation for 7 
min at 68°C (46, 48). 
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Partial 16S sequences were amplified using 0.2 mM dNTP Mix 
(Thermofisher- Invitrogen), 0.5 µM of each primer (Ric, Ric RT) with 1.5 U 
Platinum® Taq DNA Polymerase High Fidelity (Thermofisher-Invitrogen), 1x PCR 
buffer, 2.5 mM MgSO4 and 5µl DNA in a final volume of 50 µl for each reaction. 
After an initial denaturation for 3 min at 95°C, 45 cycles with denaturation for 30 sec 
94°C, annealing for 30 sec 63°C, and elongation for 120 sec at 68°C were 
performed. The PCRs were ended with a final extension for 7 min at 68°C (45, 48).  
Finally, the partial gltA gene was amplified with 0.2 mM dNTP Mix 
(Thermofisher- Invitrogen), 0.5 µM of each primer (Rh314, Rh654), 1.0 Unit 
Platinum® Taq DNA Polymerase High Fidelity (Thermofisher-Invitrogen), 1x PCR 
buffer, 2 mM MgSO4 and 5 µl DNA in a final mixture of 50 µl for each reaction. After 
an initial denaturation for 2 min at 94°C, 45 cycles with denaturation for 20 sec at 
94°C, annealing for 30 sec at 54°C and elongation for 60 sec at 68°C were 
conducted. Final extension was performed for 5 min at 68°C (47, 48). 
 PCR products were visualized in a 1.5% agarose gel and purified using the 
QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s 
recommendations. PCR product sequencing was carried out using the ABI Prism 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xl Genetic 
Analyzer (Hitachi, Japan) with the same primers as those utilized for the initial PCR 
amplification. As a sequencing control was used pGEM -3Zf(+) control template. 
Quantification of the PCR products were performed on a Fluorometer Qubit 2.0 
(Invitrogen, USA). Sequence analyses were done with Chromas Lite 2.01 (49) and 
Bioedit 7.2.5. (50). Obtained sequences were compared with sequences from GenBank 
using BLAST 2.2.32 (51, 52). 
After alignment phylogenetic trees were constructed using the Maximum 
Likelihood method based on the Tamura 3-parameter model (53) in the software 
package MEGA (54). The percentage of trees in which the associated taxa clustered 
together is shown next to the branches. Initial tree(s) for the heuristic search were 
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of 
pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
approach, and then selecting the topology with superior log likelihood value. The tree is 
drawn to scale, with branch lengths measured in the number of substitutions per site.  
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The binomial (Clopper-Pearson) 'exact' method based on the beta distribution 
was used for the calculation of 95% confidence intervals. 
The Minimum Infection Rate (MIR) was calculated as the ratio of the number of 
positive tick pools to the total number of ticks of the same species. 
 
3.4 Description of variables in questionnaires 
For each patient a questionnaire was filled out together with blood taking. The 
following variables were noted: 
- Hospital ID number: a hospital Identification number assigned a volunteer. It is 
an abbreviation of the city or district. 
- Participant ID: A Participant Identification number assigns volunteers. It was a 
letter and a four-digit number starting in 0001. No volunteer was received more 
than one number. 
- Sex of participant: is gender and categorized as (1) Male and (2) Female. 
- Name of Study site: is an area where a study was conducted and categorized as 
(1) Almaty region, (2) East Kazakhstan, (3) North Kazakhstan, (4) West 
Kazakhstan and (5) Kyzylorda. 
- When were you born: describes a date of birth. 
- How old are you: describes the age in years. 
- Present marital status: describes the marital status of the volunteer and 
- categorized as (1) Single, (2) Currently married with one spouse, (3) Married with 
two or more spouse, (4) Not married, living with permanent partner, (5) 
Separated /divorced, (6) Widowed,(7)Declined to answer,(8)Other. 
- Place of birth: describes the country of birth and categorized as (1) Kazakhstan, 
(2) Kirgizstan, (3) Uzbekistan, (4) Other countries. 
- The oblast of Kazakhstan a patient born: describes the oblast (administrative 
area) where the volunteer was born. 
- Living City/Town/Village describes the current address of a volunteer. 
- Since when have you been living in this city/Town? Village?: describes the 
cumulative years of living in the city or town or village and categorized as (1) 
Always lived in this place, (2) Years 
- Have you made any trips from your place of residence within the last month: 
describes the possible trips and categorized (1) No (2) Yes, specify 
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- The contact with wild animals: describes the possible contact with the wild animal 
and categorized as (1) Yes and (2) No 
- Bites by ticks, mosquitoes, insects or wild animals within the last month: this 
describes the possible bites of ticks, mosquitoes or wild animals and categorized 
as (1) No, (2) Yes, specify. 
- The highest level of education: This variable describes the education status of a 
volunteer and categorized as (1) Still in school, (2) Primary finished, (3) Primary 
unfinished, (4) Secondary finished, (5) Any higher education, (6) Adult education, 
(7) Have no formal education, (8) Declined to answer/Don’t know. 
- The current occupation: this variable describes the current activity and 
categorized as (1) Pupil, (2) Farmer/Peasant/plants, (3) Farmer/Peasant/animal, 
(4) Farmer/Peasant/forestry, (5) Keeping the house, (6) Unskilled laborer, (7) 
Skilled laborer, (8) Local or long distance driver, (9) Administrative or academic 
professional, (10) Businessman/woman, (11) Nurse / Physician / Clinician / 
Pharmacist, (12) Unemployed, (13) Declined to answer, (14) Other 
- How long have you been working in your current occupation: Describes the 
cumulative years of working at the current position in years. 
- How often do you usually work in the gardens and fields: Describes the 
frequency of working in the gardens or fields, categorized by (1) Yes, always, (2) 
Yes, often, (3) Yes, occasionally, (4) Yes, but rarely, (5) No, never 
- Ability to read a letter or newspaper easily, with difficulty, or not at all: describes 
the literacy level of a volunteer and categorized by (1) Easily, (2) With difficulty, 
(3) Not at all, (4) Declined to answer. 
- The total cash income of your household per year: describes the average income 
of a volunteer 
- The number of people regularly eat together in the household: describe the 
number of family members of a volunteer eat and live together. 
- The type of a flat or house: describes the current place of living of a volunteer 
and categorized by (1) Well-equipped, (2) Poorly equipped city apartment, (3) 
Private well-equipped house, (4) Poorly equipped house and (5) other 
- The storage of bulk products: describes the keeping of products and categorized 
by (1) In bags, (2) In casks, (3) Other 
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- The water source: describes from what source a volunteer gets the water and 
categorized by (1) City water pipe, (2) Rural water pipe, (3) Blow well, (4) River 
- The consumption of raw milk or raw milk products from animals: describes the 
eating of raw milk product and categorized by (1) No, (2) Yes, from which animal 
- The types and number of animals in a household: describes the animals in a 
household and categorized by the type of animal by (1) Cattle and amount. 
- Animal’s disease: describes if an animal in a household has a disease and 
categorize by (1) Yes, (2) No 
- Animal’s disease symptoms: the symptoms are described and categorized by (1) 
Unusual movement, (2) Respiratory symptoms, (3) Gastroenterological 
symptoms (4) Lesions, (5) Others 
- The death among animals: describes the cases of death among the animals and 
categorized by (1) Yes and (2) No. 
- Contact with death animals: this variable describes the possible contact with 
dead animals and categorized as (1) Yes and (2) No 
- How often direct contact to the following animals was: This variable describes the 
contact frequency with animals, the frequency estimates from 1 as the 
Always/daily, 2 - Most of the times, 3 – Rarely and 4 – Never. The determined 
animals are Cattle, Horse, Goats, Sheep, Pigs, Cats/Dogs, and Poultry. 
- The handle with raw meat: This variable describes the manipulation with raw 
meat as slaughtering, butchering, preparing for cooking and categorized by (1) 
Yes, always, (2) Yes, most of the times, (3) Yes, but barely, (4) No, never 
- How often rats/ mice or bat poop was noticed: This variable describes the 
frequency of the notice of rats/mice or bat poop. This variable categorized by (1) 
Always, (2) Most of the times (3) Rarely, (4) Never. 
- How often the rats/mice or bats were killed in the house: The variable describes 
the contact frequency with them and categorized by (1) Always (2) Most of the 
times (3) Rarely (4) Never. 
- The bird nests in the roof: this variable describes the evidence of bird nests on 
the roof and categorized by (1) Yes, (2) No, (3) Do not know 
- Bats live in your house or trees around the house: This variable describes the 
evidence of bats around the house, and it is categorized by (1) Yes, (2) No, (3) 
Do not know. 
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- The location of the house: describes the current placement of the house of a 
volunteer and categorized by (1) Rural area, (2) Urban area 
- The type of the ground around the house: describes the surrounding of the 
house and categorized by (1) Tarmac, (2) Sand, (3) Dirt 
- The look of the vegetation around the residence: This variable describes the 
possible vegetation around the house and categorized by (1) Dense 
plantation/forest, (2) Larger grass fields, (3) Occasional bush agricultural fields, 
(4) Swamp, (5) Lake, (6) Forests, (7) Others, specify. 
- The water close to your residence: This variable describes the possible water 
source and categorized by (1) Puddles after heavy rain, (2) Containers for 
collecting water, (3) Lake, (4) Steam, (5) Gully in urban area (7) No, never, (8) 
Don’t know 
- How many months per year the water around the residence is: this variable 
describes the cumulative months the quantity of months the water is around the 
house 
- Beginning of clinical symptoms: describes the time of the disease onset and 
categorized as (1) More than five days ago, (2) Less than five days ago 
- The symptoms: describes the clinical symptoms of the disease and categorized 
as (1) Fever, (2) Headache, (3) Meningism, (4) Weakness of muscles or 
joints,(5) Muscle pain or recurrent cramps, (6) Pain on swallowing, (7) Joint pain, 
(8) Stomach/abdominal pain/cramps,(9) Back pain, (10) Earache, (11) Cough, 
(12) Difficulties in speaking, hearing or seeing, (13) Seizures/epilepsy, (14) 
Difficulties in breathing, (15) Rapid breathing, (16) Sore throat, (17) Congestion 
of nose, (18) Enlarged lymph’s nodes, (19) Icterus. 
- Body temperature: describes the fever level and categorized as (1) Less than 
37.5°C, (2) More than 37.5°C. 
- Duration of high body temperature: describes the cumulative days of fever and 
categorized as (1) Less than three days and (2) 3 days and more 
- Blood pressure: describes the level of blood pressure and categorized as (1) 
Normal, (2) Hypotension, (3) Hypertension. 
- Pulse rate: describes the rate of heartbeats and categorized as (1) Less than 80, 
(2) 80-100, (3) More than 100 
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- Skin condition: describes the skin lesions and categorized as (1) Exanthema, (2) 
Ulceration, (3) Edema, (4) Others 
- Stool: describes the changes in stool and categorized as (1) Diarrhea, (2) Blood 
in stool, (3) Bright stool, (4) Other 
- Urine: describes changes in urine and categorized as (1) Blood in urine, (2) Pain 
on urinating, (3) Dark urine, (4) Low urine volume, (5) Other 
- Medications: describes a volunteer took the medicines and categorized as (1) 
Antipyretics, (2) Antirheumatics, (3) Antibiotics, (4) Other. 
- Duration of therapy: describes the cumulative days of therapy 
- Similar illness in the family or surroundings: describes the presence of similar 
symptoms within the family and categorized as (1) Yes, (2) No. 
 
3.5 Serum sampling  
For the serological investigation sera from patients with fever of unknown origin 
(FUO) were used. Paired sera (day 1, day 10-14) were collected from adolescence 
(>15 years old) and adult hospitalized patients with FUO during the warm season in 
2015 – 2016 (April – October) from 13 hospitals in the Almaty (n=9) and Kyzylorda 
(n=4) regions of Kazakhstan. FUO was defined as fever more than 3 days with high 
temperature (>37.5 ºC ear temperature) and exclusion of rheumatic fever (autoimmune 
conditions). All enrolees completed a specially designed questionnaire with 56 
questions concerning socio-demographic, living, livestock, vector habitat factors and 
clinical signs and signed informed consent forms at the time of sampling. Ethical issues 
were considered and endorsed by the national Kazakh Ethical Committees and in 
Germany by the ethical committee from the Ludwig-Maximilians University (Munich) 
respectively. For details on the questionnaire and informed consent forms see 
Appendix. 
3.6 Serological investigations by Rickettsia typhi and Rickettsia spotted fever 
group ELISA 
 Collected blood was centrifuged and separated sera were frozen in four aliquots 
at -20°C. Sera samples were tested for the presence of immunoglobulin G (IgG) and 
immunoglobulin M (IgM) antibodies against TG (R. typhi) and IgG antibodies against 
SFG of Rickettsiae by using commercial enzyme-linked immunosorbent assay (ELISA) 
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kits (Fuller Company, USA) according to the standard operating procedures (SOPs) 
and manufacturer’s guide.  
During the first step, all collected second serum samples were screened for IgG 
(R. typhi and Rickettsia SFG) with appropriate ELISA kits. At the second step, the first 
and the second sera of all positive samples were retested and titrated for IgG (R. typhi 
and Rickettsia SFG) to identify acute and exposed infection by using conforming ELISA 
kits. In a third step, the first sera of all positive samples with supposed acute infection 
(R. typhi) were screened with IgM ELISA kits. 
 
3.7 Statistical analysis 
For statistical processing of the data derived from questionnaires, the R 
statistical environment, version 3.5.3 (55) with RStudio graphical front-end, version 
1.1.463 (56) were used. 
The influence of different demographical, environmental and occupational factors 
(predictors) on the positive results of tick-borne rickettsiosis or typhus group 
rickettsiosis (outcome variables) were tested in the binomial univariate regression 
model using the glm function of the R stats package. 
At the next step, the odds ratios predicting the relationship between outcomes 
(tick-borne rickettsiosis or typhus group rickettsiosis) and factor variables were 
evaluated in the binomial multivariate model, in which factor variables were adjusted by 
confounders such as gender, age, tick bite (for tick-borne rickettsiosis) or contact with 
rodents (for typhus group rickettsiosis).  
The Fisher’s exact test was applied to evaluate the difference of clinical 
symptoms between groups positive and negative for rickettsiosis.  
P-values < 0.05 were considered as statistically significant. 
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4. Results 
4.1. Results of the tick study 
In summary, in this study six different tick species originating from six sampling 
sites in two regions in Kazakhstan were investigated. The overview of collection sites 
and investigated tick species is presented on the Figure 4.1. This were 1193 Ixodes 
persulcatus (243 pools), 578 Dermacentor marginatus (129 pools), 470 Haemaphysalis 
punctata (104 pools), 77 Hyalomma asiaticum (17 pools), 14 Dermacentor reticulatus (3 
pools) and 9 Rhipicephalus turanicus (5 pools). I. persulcatus, D. marginatus and H. 
punctata were the most abundant tick species in this PhD thesis.  
 
 
Figure 4.1 Kazakhstan, the two study regions and distribution of the tick species 
found at the sampling sites. 
 
Four tick species out of six (I. persulcatus, H. punctata, D. marginatus, D. 
reticulatus) were found in Almaty region, with three of them (I. persulcatus, H. punctata, 
D. reticulatus) only in this region. Three tick species out of six (Hy. asiaticum, Rh. 
turanicus, D. marginatus) were detected in Kyzylorda region, with two of them (Hy. 
asiaticum, Rh. turanicus) only from this region. D. marginatus was sampled much more 
often in Kyzylorda region than in Almaty region (Table 4.1).  
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Table 4.1 Overview on collected tick species originating from two regions in 
Kazakhstan. 
Localities 
(regions/districts) T
ic
k
s
 
P
o
o
ls
 I. 
persulcatus 
H. 
punctata 
D. 
marginatus  
D.  
reticulatus 
Hy. 
asiaticum  
Rh. 
turanicus 
n pools n pools n pools n pools n pools n pools 
Almaty region: 
Talgar 
Yeskeldy  
Yenbekshikazakh  
 
505 
709 
523 
 
104 
148 
113 
 
504 
610 
79 
 
103 
123 
17 
 
1 
25 
444 
 
1 
7 
96 
 
0 
60 
0 
 
0 
15 
0 
 
0 
14 
0 
 
0 
3 
0 
 
0 
0 
0 
 
0 
0 
0 
 
0 
0 
0 
 
0 
0 
0 
Sum Almaty 1737 365 1193 243 470 104 60 15 14 3 0 0 0 0 
Kyzylorda region: 
Syrdarya  
Shieli 
Zhanakorgan  
 
203 
202 
199 
 
46 
46 
44 
 
0 
0 
0 
 
0 
0 
0 
 
0 
0 
0 
 
0 
0 
0 
 
203 
199 
116 
 
46 
43 
25 
 
0 
0 
0 
 
0 
0 
0 
 
0 
0 
77 
 
0 
0 
17 
 
0 
3 
6 
 
0 
3 
2 
Sum Kyzylorda 604 136 0 0 0 0 518 114 0 0 77 17 9 5 
Total 2341 501 1193 243 470 104 578 129 14 3 77 17 9 5 
Abbreviations: I., Ixodes; H., Haemaphysalis; D., Dermacentor; Hy., Hyalomma; Rh., Rhipicephalus 
 The overall prevalence as per MIR of rickettsial DNA in the tick species and in 
the collecting localities (Almaty and Kyzylorda regions) was 42.3% (212/501; 95%CI; 
37.9 – 46.8). The largest number of the Rickettsia partial gltA real-time PCR positive 
tick pools was determined in Dermacentor (128/132; 97.0%; 95%CI; 92.4 – 99.2) 
and Haemaphysalis (80/104; 76.9%; 95%CI; 66.6 – 83.8) genera collected from three 
selected districts of Kyzylorda region (between 56.8 to100%) and in Yenbekshikazakh 
district (79/113; 69.9%; 95%CI; 60.6 – 78.2) of Almaty region (Table 4.2). The smallest 
number of the Rickettsia partial gltA real-time PCR positive tick pools was found in 
Ixodes (3/243;1.2%; 95%CI; 0.3 – 3.6) and Hyalomma (1/17; 5.9%; 95%CI; 0.2 – 
28.7) genera (Table 3) collected from Almaty region (1.9 – 11.5%) and in Zhanakorgan 
district (25/44; 56.8%; 95%CI; 41 – 71.7) of Kyzylorda region (Table 5). All Rh. 
turanicus from Zhanakorgan district of Kyzylorda region were negative in the screening 
real-time PCR. 
Moreover, the MIR was calculated for each tick species and for both selected 
regions in this study (Table 4.2 and 4.3). A high MIR of Rickettsiae was detected in 
Dermacentor (MIR=21.4 – 21.6%) and Haemaphysalis (MIR=17.0%) ticks collected 
from Yenbekshikazakh district (Almaty region, MIR=15.1%) and from the three districts 
of Kyzylorda region (MIR=12.6 – 22.7%). 
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For details on tick numbers, collection sites and MIR see Table 4.2; 4.3 and 
Figure 4.2. 
Table 4.2 Distribution of Rickettsial DNA in the collected tick species. 
Tick species  
gltA rtPCR positive [%] (number of gltA 
positive pools/total number of pools) 
Number 
of ticks 
MIR [%] (number of 
positive pools/ 
number of tested 
ticks) 
Ixodes persulcatus 1.2 (3/243) 1193 0.3 
Haemaphysalis punctata 76.9 (80/104) 470 17.0 
Dermacentor marginatus 96.9 (125/129) 578 21.6 
Dermacentor reticulatus 100 (3/3) 14 21.4 
Hyalomma asiaticum 5.9 (1/17) 77 1.3 
Rhipicephalus turanicus 0 (0/5) 9 0 
Total 42.3 (212/501) 2341 9.1 
 
 
 
Figure 4.2 Kazakhstan, the two study regions and distribution of the detected 
Rickettsia species found at the sampling sites. 
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Table 4.3 Distribution of Rickettsial DNA in the collecting localities. 
Localities 
(regions/districts) 
gltA rtPCR positive [%] (number of 
gltA positive pools/total number of 
pools) 
Number of 
ticks 
MIR [%] (number of 
positive pools/  
number of tested ticks) 
Almaty region: 
Talgar  
Yeskeldy (Tekeli city) 
Yenbekshikazakh 
 
1.9 (2/104) 
11.5 (17/148) 
69.9 (79/113) 
 
505 
709 
523 
 
0.4 
2.4 
15.1 
Kyzylorda region: 
Syrdarya 
Shieli 
Zhanakorgan 
 
100.0 (46/46) 
93.5 (43/46) 
56.8 (25/44) 
 
203 
202 
199 
 
22.7 
21.3 
12.6 
Total 42.3 (212/501) 2341 9.1 
 
As a result of MLST, Blast and afterwards phylogenetic analyses, for 209 of the 
212 Rickettsia-positive samples the Rickettsia species could be determined. In 
summary four Rickettsia spp. were identified in the molecular investigations (Tables 4.4 
– 4.6, Fig. 4.2). Two already known Rickettsia species – R. raoultii and R. slovaca – 
were identified by sequencing. R. raoultii was confirmed in 124 samples (124/209; 
59.3%; 95%CI; 52.3 – 66.1) by sequencing partial ompB (n=123), partial ompA IV 
(n=9), 23S-5S (n=9), in D. marginatus, D. reticulatus and Hy. asiaticum from Kyzylorda 
region (n=113) and around Tekeli city in Almaty region (n=11). Further, R. slovaca (n=3 
by partial ompB (n=2), partial ompAIV (n=1), 23S-5S (n=2) genes) was detected in D. 
marginatus pools only around Tekeli city in Almaty region (3/209; 1.4%; 95%CI; 0.3 – 
4.1), (Table 4.4 – 4.6, Figs. 4.3 – 4.8). 
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Table 4.4 Distribution of detected Rickettsia species in the tick species*. 
* for three samples no sequences were obtained, R., Rickettsia; I., Ixodes; H., Haemaphysalis; D., 
Dermacentor; Hy., Hyalomma; Rh., Rhipicephalus 
Table 4.5 Distribution of Rickettsia species by collecting localities. 
Localities 
(regions/districts) 
R. raoultii R. slovaca Canidatus R. 
yenbekshikazakhensis 
Genotype R. 
talgarensis 
Sum Number of 
tick pools 
Almaty region: 
Talgar district 0 0 0 2 2 104 
Yeskeldy district 
(Tekeli city) 
11 3 2 0 16 148 
Yenbekshikazakh 
district 
0 0 78 1 79 113 
Kyzylorda region: 
Syrdarya district 45 0 0 0 45 46 
Shieli district 42 0 0 0 42* 46 
Zhanakorgan district 25 0 0 0 25 44 
Total 123 3 80 3 209 501 
* for three samples no sequences were obtained 
 
Ticks R. raoultii R. slovaca Candidatus R. 
yenbekshikazakhensis 
Genotype R. 
talgarensis 
Sum Number of 
tick pools 
I. persulcatus 0 0 0 3 3 243 
H. punctata 0 0 80 0 80 104 
D. marginatus 119 3 0 0 122 129 
D. reticulatus 3 0 0 0 3 3 
Hy. asiaticum 1 0 0 0 1 17 
Rh. turanicus 0 0 0 0 0 5 
Total 123 3 80 3 209 501 
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Table 4.6 Sequences with 100% homology to known Rickettsia species. 
Rickettsia spp. ompB ompAIV 23S-5S sca4 16S gltA Total 
sequences 
R. raoultii 123 9 9 nd nd  nd 141 
R. slovaca 2 1 2 nd  nd nd  5 
Total 125 10 11 nd  nd  nd 146 
Abbreviation: nd, not determined as rickettsiae could be identified by sequences of other gene 
fragments 
 
The new “Candidatus R. yenbekshikazakhensis” was confirmed in 80 samples 
(80/209; 38.2%; 95%CI; 31.7 – 45.2) and by MLST of the partial fragments of ompB 
(n=77), ompA IV (n=30), 23S-5S (n=9), sca4 (n=34), 16S (n=6), gltA (n=35) genes 
(Table 4.4, 4.5, 4.7). “Candidatus Rickettsia yenbekshikazakhensis” has been identified 
in 16.0% of all 501 investigated tick pools (80/501; 95%CI; 12.9 – 19.5). “Candidatus R. 
yenbekshikazakhensis” was detected in high prevalence in H. punctata pools (80/104, 
76.9%) from Yenbekshikazakh district (n=78) and around Tekeli city (n=1) in Almaty 
region, respectively. This “Candidatus” species has been detected only in one tick 
species (H. punctata) collected from two districts (Yeskeldy and Yenbekshikazakh 
districts) of Almaty region (Tables 4.4, 4.5, 4.7, Figs. 4.2 – 4.8). 
We could further detect the new “genotype R. talgarensis” in three samples by 
analysis of the partial ompAIV (n=3), 23S-5S (n=2), 16S (n=2) genes in the ticks (3/209, 
1.5%) in 0.6% of all 501 tested tick pools (3/501; 95%CI; 0.1 – 1.7) (n=2341). This 
genotype was only present in I. persulcatus received from two districts (Talgar and 
Yenbekshikazakh districts) in Almaty region (Tables 4.4, 4.5, 4.7, Figs. 4.2 – 4.8). 
Unfortunately, one sample could not be sequenced and in two samples a mixture 
of different Rickettsia species was detected by sequencing of gene fragments. 
Overlapping chromatograms indicating a mixture of sequences were found for partial 
ompAIV, gltA, 16S and sca4 sequences for sample Kyzylorda 061 (D. marginatus, 
Kyzylorda region, Shieli district) and in the ompB, ompAIV and gltA sequences for 
sample Tekeli 076 (D. marginatus, Almaty region, Yeskeldy district), respectively. 
 
 
 
25 
 
Table 4.7 Overview of closest nucleotide identities of Candidatus species to the 
first hit in BLAST Rickettsia species.  
Partial 
Genes 
Maximum identity 
to known Rickettsia 
sp.  
Candidatus  
R. yenbekshikazakhensis 
Genotype 
R. talgarensis 
ompB >99.2 99.0% – CP013133, R. rhipicephali n.a. 
ompAIV 
>98.8 99.0% – U83446, R. aeschlimanni 92.7% – CP003304, R. 
canadensis  
23S-5S 
n.a. 96.1% – AY125016, R. aeschlimannii strain  88.4% – CP003304., R. 
canadensis  
16S 
>99.8 99.8% – CP003319, Ri. massiliae  
99.8% – HM050274, R. aeschlimannii strain  
99.4% – CP003319.1 
R. massiliae  
sca4 
>99.3 99.1% – HM050275, R. aeschlimannii * 
and 
98.3% - HM050275, R.aeschlimannii ° 
n.a. 
gltA 
>99.9 100% – CP015012, R. amblyommatis  
100% – KU723495, R. aeschlimannii  
100% – KT588058, R. massiliae  
n.a. 
* all sequences from Yenbenshikazakh, ° sample Tekeli 093, n.a. no sequences available for comparison 
 
All phylogenetic trees of the five different gene sequences are shown in Figure 
4.3 – 4.8 in the following pages.  
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Figure 4.3 Maximum Likelihood phylogenetic tree, based on 226 partial ompB DNA 
sequences, with 203 sequences originating from amplificates from Kazakh tick DNA 
and 23 from the GenBank database. 124 sequences from Kazakh ticks were 100% 
identical to R. raoultii, two were 100% identical to R. slovaca, and 77 sequences formed 
a new cluster “Candidatus Rickettsia yenbekshikazakhensis” (76 sequences from 
Yenbekshikazakh district, 1 from Yeskeldy district - Tekeli city). The tree with the 
highest log-likelihood (-3541.6714) is shown. There were a total of 806 positions in the 
final dataset. 
ompB 
27 
 
 
Figure 4.4 Maximum Likelihood phylogenetic tree, based on 62 partial ompAIV 
sequences, with 44 sequences originating from amplificates from Kazakh tick DNA and 
20 from the GenBank database. 10 sequences from Kazakh ticks were 100% identical 
to R. raoultii, one sequence was identical to R. slovaca. 30 sequences formed a new 
cluster “Candidatus Rickettsia yenbekshikazakhensis“ (29 sequences from 
Yenbekshikazakh district and 1 from Yeskeldy district around Tekeli city) and three a 
new cluster “genotype Rickettsia talgarensis” (1 sequence from Yenbekshikazakh 
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district, 2 from Yeskeldy district - Tekeli city). There were a total of 864 positions in the 
final dataset. The tree with the highest log-likelihood (-1803.5066) is shown. 
 
 
Figure 4.5 Maximum Likelihood phylogenetic tree, based on 40 partial 23S-5S 
sequences, with 22 sequences originating from Kazakh ticks and 18 from GenBank. 
Nine sequences from Kazakh ticks were 100% identical to R. raoultii, two sequences 
were identical to R. slovaca. Nine sequences Yenbekshikazakh district formed a new 
cluster “Candidatus Rickettsia yenbekshikazakhensis“. There were a total of 367 
positions in the final dataset. The tree with the highest log-likelihood (-1572.3294) is 
shown. 
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Figure 4.6 Maximum Likelihood phylogenetic tree, based on partial 27 partial 16S 
sequences, with 8 sequences originating from Kazakh ticks and 19 from GenBank. Six 
sequences formed a new cluster “Candidatus Rickettsia yenbekshikazakhensis” (5 
sequences from Yenbekshikazakh district, 1 from Yeskeldy district - Tekeli city) and two 
sequences from DNA of ticks from Tekeli the new cluster “genotype Rickettsia 
talgarensis”. There were a total of 717 positions in the final dataset. The tree with the 
highest log-likelihood (-1287.3794) is shown. 
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Figure 4.7 Maximum Likelihood phylogenetic tree, based on 57 partial sca4 
sequences with 34 sequences originating from Kazakh tick DNAs (33 from 
Yenbekshikazakh district, 1 from Yeskeldy district - Tekeli city) and 23 from GenBank. 
There were a total of 1.115 positions in the final dataset. The tree with the highest log-
likelihood (-4809.7101) is shown. 
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Figure 4.8 Maximum Likelihood phylogenetic tree, based on partial 55 partial gltA 
sequences, with 35 sequences originating from Kazakh tick DNAs forming the new 
“Candidatus Rickettsia yenbekshikazakhensis” (34 from Yenbekshikazakh district, 1 
from Yeskeldy district around Tekeli city) and 20 from GenBank. There were a total of 
318 positions in the final dataset. The tree with the highest log-likelihood (-641.7358) is 
shown. 
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4.2. Results of the serological study. 
Totally 950 patients with FUO from 13 hospitals of the two selected regions were 
enrolled in this study between 2015 to 2016. Only 802 (84.4%) enrolees with FUO, out 
of these, had all the requirements to be included and investigated in this study (i.e. 
collected paired serum and completely filled questionnaires), the remaining 148 patients 
(15.6%) were excluded from the study.  
Out of 802 paired serum samples, IgG antibodies to Rickettsia SFG were 
detected in 99 (26.2%; 95%CI; 22 – 30.9%) patients from Almaty region (n=378), in 151 
(35.6%; 95%CI; 31.2 – 40.3%) patients from Kyzylorda region and totally in 250 (31.2%; 
95%CI; 28.1 – 34.5%) patients from both regions (table 4.8).  
Table 4.8 Prevalence of IgG antibodies against spotted fever group of Rickettsia 
in patients presenting with fever of unknown origin in two regions of Kazakhstan 
(2015-2016). 
Localities 
(regions/hospitals) 
Acute infection1 
Previous 
infection2 
Negative samples  
Number of  
samples 
Almaty region: 
Almaty 
Taldykorgan 
Tekeli 
Usharal 
Yesyk 
Kaskelen 
Shelek 
Kabanbay 
Kapshagay 
Sum 
 
0 
0 
1 (1.2%) 
0 
0 
0 
0 
0 
0 
1 (0.3%) 
 
8 (6%) 
23 (52.3%) 
30 (35.7%) 
14 (58.3%) 
15 (25.0%) 
8 (29.6%) 
0 
0 
0 
98 (25.9%) 
 
125 (94%) 
21 (47.7%) 
53 (63.1%) 
10 (41.7%) 
45 (75.0%) 
19 (70.4%) 
4 
1 
1 
279 (73.8%) 
 
133 
44 
84 
24 
60 
27 
4 
1 
1 
378 
Kyzylorda region: 
Kyzylorda 
Syrdarya 
Shieli 
Zhanakorgan 
Sum 
 
6 (2.3%) 
1 (2.2%) 
1 (2.0%) 
2 (2.8%) 
10 (2.4%) 
 
90 (34.8%) 
9 (20.0%) 
27 (55.1%) 
15 (21.1%) 
141 (33.2%) 
 
163 (62.9%) 
35 (77.8%) 
21 (42.9%) 
54 (76.1%) 
273 (64.4%) 
 
259 
45 
49 
71 
424 
Total 11 239 552 802 
1 – shown by fourfold titer change in IgG 
2 – IgG positive sera samples including titrated samples 
 In summary 40 (5%; 95%CI; 4.7 – 6.7%) collected paired serum samples were 
titrated for IgG in order to distinguish previous and acute infections with SFG Rickettsia. 
In summary, 16 serum pairs had a low titer, eight serum pairs had a medium titer and 
16 serum pairs had a high titer (for details see table 4.9). In eleven (1.4%; 95%CI; 0.8 – 
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2.4%) of the patients from the two selected regions a fourfold increase in IgG titer 
between first and second serum was detected by ELISA indicating an acute infection 
with SFG Rickettsia (table 4.10). 
Table 4.9 Results of ELISA IgG titers against spotted fever group of Rickettsia.  
IgG titer range (1st serum / 2nd serum) Almaty region Kyzylorda region Total 
Low titer (1:100 – 1:200/1:100 – 1:200) 
Medium titer (1:100 – 1:400/1:400) 
High titer (1:100 – 1:1600/1:800 – 1:3200) 
6 
5 
4 
10 
3 
12 
16 
8 
16 
Total 15 25 40 
 All eleven patients with the evidence of an acute spotted fever group rickettsiosis 
had a fever, headache and weakness (table 4.10). Nine of the eleven patients (81%) 
complained of exanthema. Six febrile inpatients (54.5%) reported swollen lymph nodes. 
Four enrolees (36.3%) had a muscle pain and only one had a neck pain. 
Table 4.10 Patients with acute infection of the spotted fever group of Rickettsia.  
Patient No ELISA titers 
(1st/2nd serum) 
Gender/Age Exanthema History of 
tick bite 
Almaty region 
ESK-600 004 
 
1:400 / 1:1600 
 
f / 51 
 
no 
 
No 
Kyzylorda region 
KYZ2-280 023 
 
1:200 / 1:1600 
 
m / 29 
 
yes, muscle pain 
 
No 
KYZ2-280 051 1:100 / 1:800 m / 56 yes Yes 
KYZ2-280 052 1:100 / 1:400 f / 56 yes Yes 
KYZ2-280 156 1:100 / 1:800 f / 55 yes, enlarged lymph 
nodes 
Yes  
KYZ2-280 165 1:200 / 1:3200 f / 73 yes, enlarged lymph 
nodes 
Yes 
KYZ2-280 173 1:100 / 1:6400 m / 55 no, enlarged lymph 
nodes 
Yes 
SYR-250 004 1:200 / 1:1600 f / 66 yes, neck pain, muscle 
pain, enlarged lymph 
nodes 
Yes 
SHY-260 001 1:800 / 1:3200 m / 57 yes, muscle pain, 
enlarged lymph nodes 
No 
ZHA-270 001 1:100 / 1:3200 m / 57 yes, muscle pain, 
enlarged lymph nodes 
No 
ZHA-270 064 1:800 / 1:3200 f / 34 yes No 
Abbreviations: f – female, m – male 
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 IgM antibodies against typhus group of Rickettsia were identified in 15 (1.9%; 
95%CI; 1.1 – 3.1%) serum samples collected from Almaty and Kyzylorda regions (table 
4.11). The fourfold titer increase in IgG antibodies between first and second sera was 
detected by ELISA in 7 (0.9%; 95%CI; 0.4 – 1.8%) patients with FUO from both regions 
that proves the presence of an acute infection with typhus group of Rickettsia (table 
4.11). The previous infection with typhus rickettsiosis was distinguished by ELISA in 
248 (30.9%; 95%CI; 27.8 – 34.2%) feverish cases from the two selected regions (table 
4.11). 
Table 4.11 Prevalence of IgM and IgG antibodies against typhus group of 
Rickettsia in patients presenting with fever of unknown origin in two regions of 
Kazakhstan (2015-2016). 
Localities 
(regions/hospitals) 
Previous 
infection1 
Fourfold titer 
increase in 
IgG 
IgM 
positive 
samples 
Negative 
samples 
Number of  
samples 
Almaty region: 
Almaty 
Taldykorgan 
Tekeli 
Usharal 
Yesyk 
Kaskelen 
Shelek 
Kabanbay 
Kapshagay 
Sum 
 
29 (21.8%) 
29 (65.9%) 
42 (50.0%) 
16 (66.7%) 
28 (46.7%) 
14 (51.9%) 
2 (50.0%) 
1 (100%) 
0 
161 (42.6%) 
 
0  
2 (4.6%) 
0 
0 
1 (1.7%) 
0 
0 
0 
0 
3 (0.8%) 
 
2 (1.5%) 
3 (6.8%) 
1 (1.2%) 
0 
0 
2 (7.4%) 
0 
0 
0 
8 (2.1%) 
 
102 (76.7%) 
10 (22.7%) 
41 (48.8%) 
8 (33.3%) 
31 (51.6%) 
11 (40.7%) 
2 (50.0%) 
0 
1 (100%) 
206 (54.5%) 
 
133 
44 
84 
24 
60 
27 
4 
1 
1 
378 
Kyzylorda region: 
Kyzylorda 
Syrdarya 
Shieli 
Zhanakorgan 
Sum 
 
45 (17.4%) 
7 (15.6%) 
14 (28.6%) 
21 (29.6%) 
87 (20.5%) 
 
1 (0.4%) 
0 
1 (2%) 
2 (2.8%) 
4 (0.9%) 
 
5 (1.9%) 
0 
1 (2%) 
1 (1.4%) 
7 (1.7%) 
 
208 (80.3%) 
38 (84.4%) 
33 (67.4%) 
47 (66.2%) 
326 (76.9%) 
 
259 
45 
49 
71 
424 
Total 248 7 15 532 802 
1 – IgG positive sera samples including titrated samples with a titer difference lower than four-fold 
 
 Also, due to identify acute rickettsial typhus infection, 49 (6.1%; 95%CI; 4.7 – 
8%) collected serum pairs from both regions were titrated for the presence of IgG 
antibodies and 33 paired sera had a low titer, 14 paired sera had a medium titer and 
two paired sera had a high titer (table 4.12). 
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Table 4.12 Results of ELISA IgG titers against typhus group of Rickettsia. 
IgG titer range (1st serum / 2nd serum) Almaty region Kyzylorda region Total 
Low titer (1:100 – 1:200/1:100 – 1:200) 
Medium titer (1:100 – 1:400/1:400) 
High titer (1:100 /1:800) 
20 
9 
1 
13 
5 
1 
33 
14 
2 
Total 30 19 49 
 
Almost all of the patients with acute typhus rickettsiosis had unspecific clinical 
symptoms such as fever (100%), weakness (90.9%), headache (86.4%), muscle pain 
(31.8%), enlarged lymph nodes (31.8%) and neck pain (27.3%). The exanthema, which 
is the main specific rickettsial typhus symptom, was observed in 40.9% of acute cases. 
For summary see table 4.13. 
 
Table 4.13 Patients with acute infection of the typhus group of Rickettsia1.  
Patient No IgM 
reactive 
ELISA titers 
(1st/2nd 
serum) 
Gender/Age Symptoms Contact 
with 
rodents 
Almaty region      
ALM-800 012 + –  m / 25 fever, headache, 
weakness, exanthema 
No  
ALM-800 048 + – m / 21 fever, headache, neck 
pain, weakness, 
enlarged lymph nodes 
No  
TALD-900 002 + – m / 34 fever, headache, neck 
pain, weakness, 
exanthema 
No 
 
TALD-900 029 + – m / 38 fever, headache No 
TALD-900 033 + – m / 32 fever, headache, neck 
pain, weakness 
No 
TALD-900 036 - 1:100 – 1:400 m / 35 fever, neck pain, 
weakness, muscle pain, 
enlarged lymph nodes 
Yes2 
TALD-900 040 - 1:100 – 1:400 m / 32 fever, headache, 
weakness 
No 
ESK-600 017 + – m / 43 fever, headache, 
weakness 
Yes2 
YEN1-200 069 - 1:100 – 1:800 m / 19 fever, neck pain No 
KAS-700 001 + – m / 67 fever, weakness No  
KAS-700 016 + – f / 42 fever, headache, 
weakness, muscle pain 
No 
      
36 
 
Kyzylorda region 
KYZ2-280 003 - 1:100 – 1:800 f / 61 fever, headache, 
weakness, exanthema 
Yes2 
 
Kyz2-280 023 + – m / 29 fever, headache, 
weakness, muscle 
pain, exanthema 
No  
Kyz2-280 041 + – m / 56 fever, headache, 
weakness, muscle 
pain, exanthema 
No  
Kyz2-280 116 + – m / 19 fever, headache, 
weakness, enlarged 
lymph nodes 
No  
SYR-250 095 + – m / 27 fever, headache, neck 
pain, weakness, 
enlarged lymph nodes 
No  
SYR-250 106 + – m / 34 fever, headache, 
weakness, enlarged 
lymph nodes 
No  
SHY-260 001 - 1:100 – 1:400 m / 57 fever, headache, 
weakness, muscle 
pain, enlarged lymph 
nodes, exanthema 
No 
SHY-260 010 + – m / 24 fever, headache, 
weakness 
No 
 
ZHA-270 001 - 1:100 – 1:400 m / 57 fever, headache, 
weakness, muscle 
pain, enlarged lymph 
nodes, exanthema 
Yes2 
ZHA-270 038 + – m / 69 fever, headache, 
weakness, muscle 
pain, exanthema 
No 
 
ZHA-270 060 - 1:100 – 1:400 f / 60 fever, headache, 
weakness, exanthema,  
No 
1 – shown by IgM and fourfold titer change in IgG, «+» – ELISA IgM positive patients 
2 – rarely come into contact with rodents, f – female, m – male 
Among enrolees with acute spotted fever group rickettsiosis from Almaty and 
Kyzylorda regions (n=11), predominate patients aged 46 to 75 years (table 4.14). The 
median age of these inpatients from both regions was 56 years. Table 4.14 gives an 
overview on demographic, epidemiological and clinical characteristics of the patients 
with acute tick-borne rickettsiosis in two regions of Kazakhstan. 
There was defined a significant difference in age groups in tick-borne 
rickettsiosis positive results scores. Logistic regression analysis revealed an age older 
55 years as an independent predictor for this disease (odds ratio for 56-65 years age 
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group 6.01, CI 95%: 1.54:20.42; p = 0.005; odds ratio for 66-75 years age group 7.03, 
CI 95%: 1.04:29.16; p = 0.02). 
Table 4.14 Revealed features of inpatients with acute infection* of the spotted 
fever group of rickettsia in two regions of Kazakhstan (2015 – 2016) 
Factor  Number 
of 
samples 
(n=799) 
Positive 
samples 
(n=11) 
Logistic regression model 
Univariate analysis Multivariate analysis 
OR (95% CI) p-value OR a**(95% CI) p-value 
Gender Female 302 6 Reference - - - 
 Male 497 5 0.5 (0.14-1.68) 0.26 0.58 (0.17-1.98) 0.39 
        
Age, years 15-25 291 0 NAp NAp NAp NAp 
 26-35 199 2 0.67 (0.1-2.61) 0.61 0.73 (0.15-3.45) 0.69 
 36-45 121 0 NAp NAp NAp NAp 
 46-55 87 3 3.14 (0.68-11.1) 0.1 2.51 (0.64-9.83) 0.19 
 56-65 72 4 6.05 (1.55-20.56) 0.005 5.24 (1.47-18.73)  0.01 
 66-75 26 2 7.07 (1.04-29.36) 0.02 4.39 (0.84-22.94) 0.08 
    >75 3 0 NAp NAp NAp NAp 
        
Tick bite  No 620 5 Reference - - - 
 Yes 179 6 4.27 (1.27-14.96) 0.02 2.9 (0.84-10.03)  0.09 
        
Place of residence 
Urban area 
Rural area 
 
422 
377 
 
6 
5 
 
Reference 
0.93 (0.27-3.12) 
 
- 
0.91 
 
- 
0.75 (0.22-2.57) 
 
- 
0.65 
 
Contacts with wild  
animals 
No 
Yes 
      
 
 
788 
11 
 
 
10 
1 
 
 
Reference 
7.78 (0.4 – 46.92) 
 
 
- 
0.06 
 
 
- 
4.71 (0.46-48.28) 
 
 
- 
0.19 
 
Nature trip 
No 
Yes 
 
 
594 
205 
 
 
9 
2 
 
 
Reference 
0.64 (0.1-2.51) 
 
 
- 
0.57 
 
 
- 
0.6 (0.12-2.98) 
 
 
- 
0.53 
 
Garden work 
No 
Yes 
      
 
273 
526 
 
2 
9 
 
Reference 
2.36 (0.6-15.54) 
 
- 
0.27 
 
- 
1.4 (0.29-6.91) 
 
- 
0.68 
 
Livestock availability 
No 
Yes 
 
 
440 
359 
 
 
4 
7 
 
 
Reference 
2.17 (0.65-8.33) 
 
 
- 
0.22 
 
 
- 
1.71 (0.48-6.13) 
 
 
- 
0.41 
 
Current occupation 
Students 
Plants farmer 
Animals farmer 
Forestry farmer 
Keeping the house 
Unskilled labourer 
Skilled labourer 
Driver 
Adm/acad. professional 
Businessman/woman 
Nurse/physician/pharmaci
st 
Unemployed 
 
 
113 
13 
15 
8 
32 
54 
132 
27 
63 
25 
 
20 
 
 
0 
1 
0 
1 
0 
3 
1 
1 
1 
0 
 
1 
 
 
NAp 
6.47 (0.34-38.06) 
NAp 
11.16 (0.57-71.7) 
NAp 
5.42 (1.16-19.38) 
0.49 (0.03-2.59) 
3.33 (0.18-18.49) 
1.17 (0.06-6.26) 
NAp 
 
4.05 (0.22-22.79) 
 
 
NAp 
0.09 
NAp 
0.03 
NAp 
0.01 
0.49 
0.26 
0.88 
NAp 
 
0.19 
 
 
NAp 
4.8 (0.5-45.95) 
NAp 
7.79 (0.63-96.62) 
NAp 
8.1 (1.84-35.69) 
0.74 (0.09-6.16) 
4.93 (0.52-46.35) 
1.74 (0.2-15.05) 
NAp 
 
4.33 (0.47-39.6) 
 
 
NAp 
0.17 
NAp 
0.11 
NAp 
0.006 
0.78 
0.16 
0.61 
NAp 
 
0.19 
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Retiree 
Military person 
Declined_to_answer 
NA 
163 
38 
50 
26 
23 
1 
1 
0 
0 
0 
0.39 (0.02-2.04) 
2.03 (0.11-11.02) 
NAp  
NAp 
NAp 
0.37 
0.51 
NAp 
NAp 
NAp 
0.39 (0.05-3.12) 
0.17 (0.02-1.64) 
NAp 
NAp 
NAp 
0.37 
0.12 
NAp 
NAp 
NAp 
* shown by four fold titer change in IgG 
**OR – odds ratio; OR a – odds ratio adjusted for gender, age and tick bite rate; CI – confidence interval; 
NA – not available; NAp – not applicable 
 
The chance to observe a positive tick-borne rickettsiosis in the group bitten by a 
tick is 4.33 times higher than in the group of not bitten persons (CI95%: 1.28:15.18; p = 
0.017). However, the association between the disease and a tick bite is strongly 
confounded by age due to the prevalence of a rickettsiosis positive result is much 
higher in older age groups. Therefore, after adjustment for age the association between 
a tick bite and disease is no longer significant (OR = 2.91, CI 95%: 0.84:10.08; p = 
0,092). 
Our analysis revealed statistically significant association between work in 
forestry and chance of positive results for rickettsiosis (OR = 11.1, CI 95%: 0.57:71.24; 
p = 0.03), moreover, the risk group was unskilled labourers (OR = 5.38, CI 95%: 
1.15:19.25; p = 0.02). 
Almost half of the febrile participants showing an acute SFG rickettsiosis (n=5) 
are males. The same pattern we have found with a place of residence: five patients are 
living in a rural area and six patients in the urban area. The majority of inpatients with 
acute tick-borne rickettsiosis (81.8%, n=9) didn’t have any trip to the nature during the 
last month. At the same time most of them (72.7%, n=8) did a daily garden work. Six 
enrolees out of eleven (%) had a tick bite during the past month. In 63.6% of acute 
cases (n=7), daily contact with livestock was observed (table 4.14).  
Patients with acute infection (n=11) had not only unspecific mild clinical 
symptoms such as fever (100%), headache (100%), weakness (81.8%) but also some 
distinctive signs as enlarged regional lymph nodes (54.5%) and exanthema (81.8%) 
(table 4.15). 
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Table 4.15 Clinical manifestations in patients with acute infection* of the spotted 
fever group of rickettsia**. 
Symptoms OR (CI 95%) p-value 
Neck pain 0.29 (0.01 – 2.09) 0.31 
Weakness 4.34 (0.61 – 189.02) 0.19 
Muscle pain 2.31 (0.49 – 9.23) 0.24 
Lymphadenopathy 1.82 (0.46 – 7.61) 0.36 
Exanthema 16.28 (3.32 – 156.08) 0.00004 
*  shown by four fold titer change in IgG 
** data based on Fisher’s exact test; OR – odds ratio; CI – confidence interval 
 
The demographic, epidemiological and clinical characteristics of the acute cases 
with rickettsial typhus in two regions of Kazakhstan are presented in table 4.16 and 
4.17. Among the participants with acute infection of the typhus group Rickettsia (n=22), 
the persons aged between 15 to 35 years (n=12). The median age of these inpatients 
from both regions was 34.5 years. 
The majority of feverish patients with acute rickettsial typhus infection (81.8%, 
n=18) are males. Less than half of these enrolees (45.5%, n=10) are living in a rural 
area. In many acute cases the contacts with wild animals (95.6%, n=21), with rodents 
(81.8%, n=18) and trip to the nature (68.2%, n=15) didn’t observe. The 59.1% of acute 
patients (n=13) have a daily contact with their livestock (table 4.16).  
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Table 4.16 Revealed features of inpatients with acute infection* of the typhus 
group of Rickettsia in two regions of Kazakhstan (2015 – 2016). 
Factor  Number 
of 
samples 
(n=799) 
Positive 
samples 
(n=22) 
Logistic regression model 
Univariate analysis Multivariate analysis 
OR (95% CI) p-value OR a**(95% CI) p-value 
Gender Female 302 4 Reference - - - 
 Male 497 18 2.8 (1.03-9.76) 0.06 3.05 (1.02-9.16) 0.05 
        
Age, years 15-25 291 5 0.5 (0.16-1.29) 0.18 0.46 (0.16-1.27) 0.13 
 26-35 199 7 1.42 (0.54-3.42) 0.45 1.49 (0.59-3.71) 0.4 
 36-45 121 3 0.88 (0.2-2.64) 0.84 0.85 (0.25-2.92) 0.79 
 46-55 87 0 NAp NAp NAp NAp 
 56-65 72 5 3.12 (1-8.17) 0.03 3.37 (1.19-9.58) 0.02 
 66-75 26 2 3.14 (0.48-11.62) 0.14 3.58 (0.78-16.46) 0.1 
    >75 3 0 NAp NAp NAp NAp 
        
Contact with rodents  
No 
 
696 
 
18 
 
Reference 
 
- 
 
- 
 
- 
 Yes 103 4 1.07 (0.25-3.21) 0.92 0.87 (0.25-3.04) 0.83 
        
Place of residence 
Urban area 
Rural area 
 
422 
377 
 
12 
10 
 
Reference 
0.93 (0.39-2.18) 
 
- 
0.87 
 
- 
0.89 (0.37-2.13) 
 
- 
0.79 
 
Contacts with wild  
animals 
No 
Yes 
      
 
 
788 
11 
 
 
21 
1 
 
 
Reference 
3.65 (0.19-20.42) 
 
 
- 
0.23 
 
 
- 
2.98 (0.34-26.39) 
 
 
- 
0.33 
 
Nature trip 
No 
Yes 
 
 
594 
205 
 
 
15 
7 
 
 
Reference 
1.36 (0.51-3.29) 
 
 
- 
0.5 
 
 
- 
1.26 (0.5-3.17) 
 
 
- 
0.62 
 
Garden work 
No 
Yes 
      
 
273 
526 
 
9 
13 
 
Reference 
0.74 (0.32-1.82) 
 
- 
0.5 
 
- 
0.64 (0.27-1.54) 
 
- 
0.32 
 
Livestock availability 
No 
Yes 
 
 
440 
359 
 
 
9 
13 
 
 
Reference 
1.49 (0.63-3.56) 
 
 
- 
0.36 
 
 
- 
1.43 (0.6-3.39) 
 
 
- 
0.41 
 
Current occupation 
Students 
Plants farmer 
Animals farmer 
Forestry farmer 
Keeping the house 
Unskilled labourer 
Skilled labourer 
Driver 
Adm/acad. professional 
Businessman/woman 
Nurse/physician/pharmaci
st 
Unemployed 
Retiree 
Military person 
 
 
113 
13 
15 
8 
32 
54 
132 
27 
63 
25 
 
20 
163 
38 
50 
 
 
0 
1 
0 
0 
0 
1 
3 
2 
3 
0 
 
0 
6 
3 
2 
 
 
NAp 
3.04 (0.16-16.53) 
NAp 
NAp 
NAp 
0.65 (0.04:3.18)  
0.79 (0.18-2.37) 
3.01 (0.46-11.1) 
1.89 (0.43-5.74) 
NAp 
 
NAp 
1.48 (0.52-3.67) 
3.35 (0.76-10.42) 
1.52 (0.24-5.41)  
 
 
NAp 
0.3 
NAp 
NAp 
NAp 
0.68 
0.71 
0.15 
0.32 
NAp 
 
NAp 
0.42 
0.06 
0.58 
 
 
NAp 
1.96 (0.23-16.43) 
NAp 
NAp 
NAp 
0.6 (0.08-4.54) 
0.76 (0.22-2.65) 
2.06 (0.44-9.59) 
2.39 (0.67-8.52) 
NAp 
 
NAp 
1.57 (0.6-4.13) 
2.42 (0.46-12.64) 
1.87 (0.38-9.29) 
 
 
NAp 
0.54 
NAp 
NAp 
NAp 
0.62 
0.67 
0.36 
0.18 
NAp 
 
NAp 
0.36 
0.3 
0.44 
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Declined_to_answer 
NA 
26 
23 
1 
0 
1.43 (0.08-7.29) 
NAp 
0.73 
NAp 
0.89 (0.11-7.09) 
NAp 
0.91 
NAp 
*shown by IgM and four fold titer change in IgG 
**OR – odds ratio; OR a – odds ratio adjusted for gender, age and contact with rodents; CI – confidence 
interval; NA – not available; NAp – not applicable 
 
Table 4.17 Clinical manifestations in patients with acute infection* of the typhus 
group of Rickettsia**. 
Symptoms OR (CI 95%) p-value 
Neck pain 1.12 (0.35 – 3.06) 0.81 
Weakness 4.4 (1.05 – 39.11) 0.03 
Muscle pain 1.9 (0.64 – 5.06) 0.18 
Lymphadenopathy 0.7 (0.24 – 1.84) 0.51 
Exanthema 2.47 (0.91 – 6.36) 0.06 
*  shown by IgM and four fold titer change in IgG 
** data based on Fisher’s exact test; OR – odds ratio; CI – confidence interval 
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5. Discussion 
5.1. Discussion of tick study 
The spotted-fever group of rickettsiae in tick study was for the first time a large-
scale and comprehensive investigation performed in two selected pilot regions of 
Kazakhstan. The two regions have different landscapes and this is the reason that in 
both selected regions several different tick species have been flagged. Dermacentor 
marginatus is the most abundant tick typically found at the collection sites in the desert 
and semi-desert landscape of Kyzylorda region (16) which is the classical habitat of this 
tick species (37, 38). However, the three selected collection sites in Almaty region is a 
mountainous landscape covered with forest (Almaty region of Kazakhstan. 
http://zhetysu.gov.kz/ru/o-regione/) which are the typical habitats for Ixodes ticks (37) 
having in Almaty region the highest abundance of all flagged tick species (48.1%). In 
Almaty region the highest variability of tick species with five tick species (I. persulcatus, 
H. punctata, D. marginatus, D. reticulatus) was found. 
The taxonomic classification of ticks investigated in this study was done using 
morphologic markers (17-21). D. marginatus and D. niveus were summed up to 
Dermacentor marginatus as the Editor of Parasites and Vectors stated that these are 
conspecific. Genetic markers give a hint on that statement, however detailed data are 
lacking (39-41). 
The results of my studies clearly show that five of the seven collected tick 
species carry rickettsial DNA. In Kyzylorda region where Dermacentor species are the 
main species, 56.8-100% of the ticks’ pools were Rickettsia positive, and only R. raoultii 
was found in the two species of Dermacentor, D. marginatus and D. reticulatus. 
Interestingly at the three tick flagging sites in Almaty region, which has been considered 
so far as a non-endemic region, four Rickettsia species are present, indicating the 
highest variability of Rickettsia in ticks. In 59% of the tick pools R. raoultii and in three 
pools R. slovaca were found – the important point is that these two species are 
pathogenic for humans. The obtained data indicate that the main vectors of these two 
pathogens are Dermacentor ticks, which is in line with data from neighboring countries 
i.e. Russian Federation, Mongolia or northwestern China which is located close to 
Almaty region of Kazakhstan (7, 42 – 50). An important point of my study is, that R. 
raoultii was for the first time detected in one Hy. asiaticum tick pool collected from 
Kyzylorda region of Kazakhstan.  
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R. raoultii and R. slovaca are well described human pathogens that cause the 
“SENLAT” (scalp eschar and neck lymphadenopathy) syndrome manifested by scalp 
eschars and neck lymphadenopathy, TIBOLA (tick-borne lymphadenopathy) or 
DEBONEL (Dermacentor-borne necrosis erythema lymphadenopathy) after a tick bite 
(7, 51). The high Minimum Infection Rate of R. raoultii in the studied ticks and a recent 
case study in China were 26 cases of R. raoultii infections with varying severity were 
published (52), indicate that R. raoultii should be included in the diagnosis of 
rickettsioses in Kazakhstan. The occurrence of R. slovaca was before described in the 
sheep ked (Melophagus ovinus) sampled in the localities of Xinjiang Uygur Autonomous 
Region (northwestern China), that is neighboring the Almaty region of Kazakhstan (48). 
My studies show that R. slovaca is present in Kazakhstan – so further studies are 
needed to clarify the role of this tick for diseases in humans and to check if it is 
abundant in other regions in Kazakhstan. 
I describe for the first time a new Candidatus Rickettsia in Kazakhstan, the 
“Candidatus R. yenbekshikazakhensis” was confirmed by MLST of six gene fragments. 
For the ompB, 23S-5S, 16S and sca4 but not for the ompAIV and gltA it fulfills the 
criteria of Fournier et al., (2003) (8) to designate it as a new “Candidatus” species (table 
4.7). It has been suggested to taxonomically classify Rickettsia as new “Candidatus” if 
at least four or five sequences are newly described (4, 8–10). The closest species to 
“Candidatus R. yenbekshikazakhensis” is R. massiliae which is also known to be 
human pathogenic and to induce SENLAT syndrome (53, 54). The new “Candidatus R. 
yenbekshikazakhensis” was detected in two regions and in 87.6% of all investigated H. 
punctata ticks, which indicates that this tick species might be its main vector. 
Further “genotype R. talgarensis” was detected in three tick pools. The analysis 
of three gene fragments, ompAIV, 23S-5S and 16S could be performed showing a quite 
high divergence to all known Rickettsiae (table 4.7). The detected agent fulfills therefore 
the criteria to be describe as new genotype (8). For both, “Candidatus R. 
yenbekshikazakhensis” and “genotype R. talgarensis” further studies are needed to 
clarify their role as pathogen for humans. 
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5.1. Discussion of serological study 
The serological study described in this thesis was designed as a cross sectional 
investigation of inpatients with fever of unknown origin hospitalized in two selected 
southern regions of Kazakhstan. It is the first study to examine the causative agents of 
fever of undetermined origin in Kazakhstan. This study was focused on both rickettsial 
diseases – tick-borne rickettsiosis and typhus group rickettsiosis – as a cause of acute 
febrile response. We demonstrated that the typhus group rickettsia in comparison to 
tick-transmitted rickettsia two times more can be the cause of the fever of obscure 
origin in hospital-enrolled patients from Almaty and Kyzylorda regions of Kazakhstan.  
 This study had a number of limitations. 802 out of 950 feverish inpatients 
donated 1st and 2nd serum samples, complete questionnaires and the prevalence of 
acute tick-bite rickettsiosis among febrile patients was based only on the detection of 
the four-fold IgG titer differences in the 2nd serum samples. The prevalence of acute 
spotted fever group rickettsiosis in Almaty region was much lower than that observed 
among febrile enrolees from Kyzylorda region. This obtained data once again prove the 
endemicity of Kyzylorda region for this rickettsial disease in comparison with Almaty 
region. The prevalence of acute typhus group rickettsiosis in our study was based on 
the detection of IgM in the 1st sera and the four-fold titer changes in IgG of the 2nd 
serum samples. The prevalence of this acute rickettsial disease in Almaty region was 
similar to that observed among inpatients with undetermined hyperthermia in Kyzylorda 
regions. 
 This is the first comprehensive study on both groups of Rickettsia as a potential 
to cause the fever of unknown origin in humans. The received data shows that tick-
borne rickettsiosis and rickettsial typhus are present in Kazakhstan. Most of the Kazakh 
general clinicians are not familiar with the symptoms caused by rickettsial diseases and 
therefore many cases probably remain undiagnosed in our country. Therefore, it is very 
important to raise awareness of these emerging diseases in Kazakhstan. 
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6. Conclusion 
6.1 Conclusion 
In this thesis I made first in depth investigations on tick borne Rickettsia in ticks 
and as cause of FUO and for the first-time generated data on Rickettsia of the typhoid 
group -associated FUO.  
In the first part of this thesis I describe the first, very detailed investigation of 
Rickettsia in ticks and for the first time MLST of the positive found samples. I found out, 
that the prevalence expressed as MIR of SFG rickettsial DNA in the tick species and in 
the collecting localities (Almaty and Kyzylorda regions) was with 42.3% quite high. 
Further in Dermacentor (97.0%) and Haemaphysalis (76.0%) genera collected from 
three selected districts of Kyzylorda region (between 56.8 to100%) and in 
Yenbekshikazakh district (79/113; 69.9%; 95%CI; 60.6 – 78.2) of Almaty region there 
were tremendous prevalences of SFG rickettsial DNA. In addition, I describe for the 
first-time details on Rickettsia species in ticks. Interestingly four Rickettsia species were 
found and most exciting two of these are unknown Rickettsia species, which was 
confirmed by several rickettsia DNA fragments. Remarkably Almaty region was so far 
not seen as endemic region for SFG Rickettsia.  
Additionally, in the second part this thesis contains comprehensive data on SFG 
and murine typhus-Rickettsia specific antibodies in patients suffering on FUO. Despite 
we only could get 802 paired sera samples and questionnaires for SFG we IgG 
antibodies to Rickettsia SFG in 26.2% of the patients from Almaty region and in 35.6% 
from Kyzylorda region, with an average percentage lying at 31.2%. Acute SFG 
infections were detected in both oblasts in patients with FUO, with symptoms classically 
fund in different SFG rickettsiosis. In addition, I describe for the first time the presence 
of murine typhus in Kazakhstan, which is officially not registered in my country. These 
findings are of importance and I could even show that not only previous but also acute 
infections are present in over 6.1% of investigated samples from patients with FUO.  
In summary the results of this thesis show that spotted fever and murine typhus 
might be of higher concern as thought before and that FUO has to be taken into 
account. 
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6.2 Recommendations 
  The clinical cases of tick-borne rickettsioses, which were registered by using 
CFT over the past 20 years in Kazakhstan, are so far not confirmed by other serological 
methods such as ELISA and by pathogen detection (e.g. rickettsial DNA by PCR). With 
the rising evidence on the relevance of rickettsiae in human infections and for improving 
epidemiological data, routine laboratory diagnostic tools must be implemented in all 
reporting laboratories in Kazakhstan. Our data also indicate that clinicians should be 
aware of SENLAT syndrome which is caused by two confirmed pathogens (R. raoultii 
and R. slovaca) circulating in the territory of Almaty and Kyzylorda regions. The present 
data indicate that tick-borne rickettsiae and associated pathological conditions in 
humans should be further investigated in all regions of Kazakhstan to estimate the 
importance and clinical impact caused by all four described rickettsiae. 
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Statement on Pre-release and Contribution 
 Two scientific articles from this study were prepared for publication. The first 
article has already been accepted for publication to the target journal “Parasites and 
Vectors” and is in the process of production. The title of the accepted article is 
“Prevalence of Rickettsia species in ticks including identification of unknown species in 
two regions in Kazakhstan”.  
 The second article entitled “Seroprevalence of rickettsiae in hospital-enrolled 
patients with fever of unknown origin in the southern regions of Kazakhstan” is 
presently under correction by co-authors for the submission to Parasites and Vectors 
journal. 
 The PhD candidate collected the tick and serum samples for investigation and 
with the help of trained medical doctors and sanitary specialists of medical facilities 
from pilot regions and Scientific Practical Centre for Sanitary Epidemiological Expertise 
and Monitoring. All laboratory work including tick sorting, homogenization, sample 
inactivation, DNA extraction, conducting real-time PCR, conventional PCR, ELISA tests 
and received data analysis were done by the PhD candidate under the close support of 
the direct supervisor. PhD candidate also wrote two articles and PhD thesis under the 
close supervision of all supervisors. 
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Informed Consent Form  
“Study of Patients with Fever of unknown origin due to selected Infectious 
Diseases in five regions (oblasts) of Kazakhstan”  
You are being invited to join this research study because we want to find out if you have 
an acute infection with certain bacteria and viruses. It is possible to do a blood test to 
see if you have been exposed to these infections, either recently or long ago. After a 
person is exposed to a virus or bacteria, they produce substances called antibodies. 
Antibodies are proteins made by the body's natural defense system (immune system) to 
attack and destroy foreign substances, such as bacteria and viruses. 
These antibodies can remain in the blood of people for many years after exposure to 
the infection. This study is designed to measure antibodies against some infections.  
The infections to be studied include brucellosis, leptospirosis, leishmaniosis, 
meloidosis, glanders, borreliosis, erlichiosis, anaplasmosis, Q-fever, spotted fever, 
plague, anthrax, tularaemia, typhus group and scrub typhus group rickettsioses, tick-
borne encephalitis (TBE), West Nile fever, Dengue virus infections, Japanese 
encephalitis, California encephalitis, Sindbis virus infection, Tahyna virus infection, 
Congo-Crimean Hemorrhagic Fever (CCHF), sandfly viruses, hanta- and enterovirus. 
We are testing you to determine if you have an active infection with these bacteria or 
viruses.  
Purposes of this Study:  
1. To see how many hospitalized people in Kazakhstan have antibodies to the 
infections mentioned above.  
2. To figure out risk factors associated with prior exposure to these infections  
3. To aid in the development of future scientific research and developing preventative 
programs and treatment of disease  
Eligibility for Participation:  
To join this study, you have a onging fever where the reason is not known for.  
You cannot join this research study if you are less than 15 years of age.  
Screening Procedures:  
If you agree to participate in this study, one of the study team members will ask about 
your understanding of the study and if you have any questions. They will make sure you 
are eligible to participate in the study.  
Collection of Samples:  
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We will draw approximately 20 ml (approximately four teaspoons) of blood from a vein 
in your arm twice: in the day of hospitalization and on 7-14 day of disease. We will also 
ask you some questions about the possibility that you have had a prior exposure to the 
infections to be studied. You will not have to do anything other than give blood and 
answer questions. As a volunteer you do not have to answer any question(s) about 
which you feel uncomfortable.  
Specimen Testing:  
Your blood will be tested for antibodies against the infections we mentioned earlier in 
the consent form. Testing could occur at the Bundeswehr Institute of Microbiology 
(InstMikroBioBw, Germany), at the SPC SEEM, in Kazakhstan, at the KazNMU 
(Kazakhstan) or even laboratories at other places in the world (see future testing 
section). 
Test Results:  
We will not inform you of the results of the testing. It is important that you understand 
that a positive result may mean you had one of these infections in the past. It does not 
mean that you are infected now. Therefore, the results of these tests do not affect your 
current health status.  
Future testing:  
We would like to save some of your blood sample for future tests possibly at 
Kazakhstan and German laboratories, or possibly other laboratories in other countries. 
At the end of this form, you will have the opportunity to decide whether or not to allow 
us to do that. Because medical technology is changing rapidly, we cannot tell you with 
confidence what types of studies we might conduct. However, any future studies will be 
limited to research broadly related to the present research objectives. Any sample of 
your blood used for future testing will be labelled only with a study number and will not 
be linked to any of your personal information. You will not receive a report on any 
results that may come from future studies.  
Duration of Study:  
Your participation in this study will take approximately 20 minutes. If you agree to future 
testing, we will retain your blood sample at the SPC SEEM, the KazNMU and the 
InstMikroBioBw, for 10 years. If you do not agree to future testing, we will dispose of 
your blood sample at the end of the study. We will retain papers from the study and the 
data at the SPC SEEM, the KazNMU and the InstMikroBioBw for 10 years.  
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Foreseeable Risks or Discomforts:  
There are several small risks to participating in this study. There could be some 
discomfort associated with the needle stick for a blood draw. You could have swelling or 
bruising, and there is a small risk of infection at the site of the needle stick. Although 
most people have no infection or noticeable swelling, it cannot be prevented in all 
cases. In the majority of cases, such bruises will go away by themselves in 1 to 2 
weeks. A few people feel light-headed and may develop a fast heartbeat during blood 
collection. These symptoms can be halted by having you lay down and/or by stopping 
the procedure. Rarely, you may develop a blood clot at the site of the blood draw. The 
area around this blood clot can become red and painful. The bump associated with the 
blood clot can persist for many weeks. These are the risks of obtaining blood samples, 
but significant complications do not often occur. 
There is a small risk that your confidentiality may be breached. Measures to protect 
your personal information will be described in detail.  
Benefit to Subject:  
There is no direct medical/health benefit to you by participating in this study. However, 
this study may benefit the health of people in your community in the future.  
Circumstances of Withdrawal:  
Your participation is voluntary. You may withdraw from this study at any time without 
losing any benefits that you would otherwise have. Your participation may also be 
terminated without your consent if health conditions or other conditions occur that might 
be dangerous or detrimental to your health, you fail to comply with the procedures 
outlined in this informed consent, or the Sponsor terminates this study.  
Confidentiality of Volunteers:  
All data and medical information obtained about you, as an individual, will be 
considered privileged and held in confidence. You will not be identified by name in any 
published report or presentation of the results. The Kazakhstan authorities will receive a 
report containing grouped results, but will not be able to identify you individually. As part 
of their responsibility to oversee research and ensure protection of volunteers, the 
Kazakhstan authorities may inspect the records of this research. Regulatory groups in 
Kazakhstan and German Science Institutions may also inspect the records of this 
research. By signing this consent form, you agree to such inspection and disclosure. 
Complete confidentiality cannot be promised to volunteers because reporting 
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information to appropriate medical or command authorities about your health may be 
required. Kazakhstan law requires us to ask for your permission to use your information 
for research. You can stop us from using your information at any time by contacting us 
and asking us to stop. Signing the informed consent form you agree to participate in 
study.  
CONSENT for the Use of Your Samples for Future Studies:  
There is a possibility that the blood sample you are donating during this study may be 
used in other research studies and for other types of research tests. These tests may 
be performed possibly at the SPC SEEM, the KazNMU in Kazakhstan and the 
InstMikroBioBw in Germany, or possibly other laboratories in other countries. You will 
not be notified of future uses of your sample. Please indicate your willingness to permit 
this use of your donated sample by signing the appropriate statement:  
 
Sample can be stored for future use for up to 10 years 
Sample may be used in other research studies in the future 
 
_______________________  
 
Sample has to be used in the current study only.  
Sample cannot be stored for future use. 
 
______________________  
 
CONSENT for Participation in the Research Study:  
Your signature below indicates that you have read this informed consent document, the 
research study has been explained to you and your questions have been answered, 
and you agree to take part in this study. You will receive a copy of this signed form.  
 
___________________________________  
Printed Name of Volunteer  
 
___________________________________  
Permanent Address of Volunteer  
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___________________________________  
Printed Name of Person Conducting the  
Informed Consent Discussion  
 
___________________________________ ___________________  
Signature of Person Conducting the Date (dd/mm/yyyy)  
Informed Consent Discussion  
 
___________________________________  
Printed Name of Witness (if applicable)  
 
___________________________________ ___________________  
Signature of Witness (if applicable) Date (dd/mm/yyyy) 
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Informed Consent Form 
Informed Consent Document for parents of children (15 years and older) 
participating in “Study of Patients with Fever of unknown origin due to selected 
Infectious Diseases in five regions (oblasts) of Kazakhstan”  
Children with acute and current fever may have an acute infectious disease with certain 
bacteria and viruses. For these reasons, we want to test the blood of your child. We can 
with this test see if your child has been exposed to these infections, either recently or 
long ago. After a person is exposed to a virus or bacteria, they produce substances 
called antibodies. Antibodies are proteins made by the body's natural defense system 
(immune system) to attack and destroy foreign substances, such as bacteria and 
viruses. These antibodies can remain in the blood of people for many years after 
exposure to the infection. This study is designed to measure antibodies against some 
infections in children between 15 and 18 years.  
The infections to be studied include brucellosis, leptospirosis, leishmaniosis, 
meloidosis, glanders, borreliosis, erlichiosis, anaplasmosis, Q-fever, spotted fever, 
plague, anthrax, tularaemia,typhus group and scrub typhus group rickettsioses, tick-
borne encephalitis (TBE), West Nile fever, Dengue virus infections, Japanese 
encephalitis, California encephalitis, Sindbis virus infection, Tahyna virus infection, 
Congo-Crimean Hemorrhagic Fever (CCHF), sandfly viruses, hanta- and enterovirus. 
We are testing your child to determine if it has an active infection with these bacteria or 
viruses.  
Purposes of this Study:  
1. To see how many hospitalized children in Kazakhstan have antibodies to the 
infections mentioned above.  
2. To figure out risk factors associated with prior exposure to these infections  
3. To aid in the development of future scientific research and developing preventative 
programs and treatment of disease  
Eligibility for Participation:  
To join this study, your child should have an ongoing fever where the reason is not 
known for.  
As rule, a child is legally unable to provide informed consent. For this reason before 
testing your child (<15 years) for mentioned above infections You (Parent(s)/legal 
guardian) have to sign an Informed Signed Form. You have the right to refuse to sign 
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this form without any justification nor prejudice in regard to services provided to him by 
the hospital. According to Kazakh ethics rules and Good Clinical Practice for the 
protection of people rights, a child cannot be included in this project without the parent’s 
or his legal guardian’s signature. Copies of the Informed Consent Form together with 
this Information Notice will be handed to you for your record if you accept that your child 
participates in this project.  
Screening Procedures:  
If you agree that your child participates in this study, one of the study team members 
will ask about your understanding of the study. If you have any questions, they will 
make sure that your child is eligible to participate in the study.  
Collection of Samples:  
We will draw approximately 20 ml (approximately four teaspoons) of blood from a vein 
in the arm of your child twice: in the day of hospitalization and on 7-14 day of disease. 
We will also ask you and your child some questions about the possibility that you have 
had a prior exposure to the infections to be studied. Your child will not have to do 
anything other than give blood and with your help to the answer questions. As a 
volunteer your child does not have to answer any question(s) about you or your child 
feel uncomfortable.  
Specimen Testing:  
The blood sample of your child will be tested for antibodies against the infections we 
mentioned earlier in the consent form. Testing could occur at the Bundeswehr Institute 
of Microbiology (InstMikroBioBw, Germany), at the SPC SEEM, in Kazakhstan, at the 
KazNMU (Kazakhstan) or even laboratories at other places in the world (see future 
testing section).  
Test Results:  
We will not inform you and your child of the results of the testing. It is important that you 
understand that a positive result may mean your child had one of these infections in the 
past. It does not mean that your child is infected now. Therefore, the results of these 
tests do not affect the current health status of your child.  
Future testing:  
We would like to save some of your child blood sample for future tests possibly at 
Kazakhstan and German laboratories, or possibly other laboratories in other countries. 
At the end of this form, you will have the opportunity to decide whether or not to allow 
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us to do that. Because medical technology is changing rapidly, we cannot tell you with 
confidence what types of studies we might conduct. However, any future studies will be 
limited to research broadly related to the present research objectives. Any sample of 
your blood used for future testing will be labelled only with a study number and will not 
be linked to any of your personal information. You and your child will not receive a 
report on any results that may come from future studies.  
Duration of Study:  
The participation of your child in this study will take approximately 20 minutes. If you 
agree to future testing, we will retain blood sample of your child at the SPC SEEM, the 
KazNMU and the InstMikroBioBw, for 10 years. If you do not agree to future testing, we 
will dispose of this blood sample at the end of the study. We will retain papers from the 
study and the data at the SPC SEEM, the KazNMU and the InstMikroBioBw for 10 
years.  
Foreseeable Risks or Discomforts:  
There are several small risks to participating in this study. There could be some 
discomfort associated with the needle stick for a blood draw. Your child could have 
swelling or bruising, and there is a small risk of infection at the site of the needle stick. 
Although most people have no infection or noticeable swelling, it cannot be prevented in 
all cases. In the majority of cases, such bruises will go away by themselves in 1 to 2 
weeks. A few people feel light-headed and may develop a fast heartbeat during blood 
collection. These symptoms can be halted by having you lay down and/or by stopping 
the procedure. Rarely, your child may develop a blood clot at the site of the blood draw. 
The area around this blood clot can become red and painful. The bump associated with 
the blood clot can persist for many weeks. These are the risks of obtaining blood 
samples, but significant complications do not often occur.  
There is a small risk that your child confidentiality may be breached. Measures to 
protect his/her personal information will be described in detail.  
Benefit to Subject:  
There is no direct medical/health benefit to your child by participating in this study. 
However, this study may benefit the health of people in your community in the future  
Circumstances of Withdrawal:  
The participation of your child in this study research is voluntary. Your child may 
withdraw from this study at any time without losing any benefits that you would 
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otherwise have. The participation of your child may also be terminated without your 
consent if your child health conditions or other conditions occur that might be 
dangerous or detrimental to his/her health, you or your child fail to comply with the 
procedures outlined in this informed consent, or the Sponsor terminates this study. 
Confidentiality of Volunteers:  
All data and medical information obtained about your child, as an individual, will be 
considered privileged and held in confidence. Your child will not be identified by name 
in any published report or presentation of the results. The Kazakhstan authorities will 
receive a report containing grouped results, but will not be able to identify your child 
individually. As part of their responsibility to oversee research and ensure protection of 
volunteers, the Kazakhstan authorities may inspect the records of this research. 
Regulatory groups in Kazakhstan and German Science Institutions may also inspect the 
records of this research. By signing this consent form, you agree to such inspection and 
disclosure. Complete confidentiality cannot be promised to volunteers because 
reporting information to appropriate medical or command authorities about your child 
health may be required. Kazakhstan law requires us to ask for your permission to use 
your information for research. You can stop us from using your child information at any 
time by contacting us and asking us to stop. Signing the informed consent form you 
give the permission and agreement to your child to participate in study.  
CONSENT for the Use of your child blood samples for Future Studies:  
There is a possibility that the blood sample your child is donating during this study may 
be used in other research studies and for other types of research tests. These tests 
may be performed possibly at the SPC SEEM, the KazNMU in Kazakhstan and the 
InstMikroBioBw in Germany, or possibly other laboratories in other countries. You and 
your child will not be notified of future uses of your sample. Please indicate your 
willingness to permit this use of your child donated sample by signing the appropriate 
statement:  
Sample can be stored for future use for up to 10 years  
Sample may be used in other research studies in the future 
 
____________________  
Sample has to be used in the current study only.  
Sample cannot be stored for future use. _______________________  
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CONSENT for Participation in the Research Study:  
Your signature below indicates that you have read this informed consent document, the 
research study has been explained to you and your questions have been answered, 
and you give the permission to your child to take part in this study. You and your child 
will receive a copy of this signed form.  
 
____________________________________________________  
Printed Name of Volunteer (a pediatric subject)  
 
_____________________________________________________  
Printed Name of parent’s(s)/ a legal guardian  
 
_____________________________________________________  
Permanent Address of Volunteer (a pediatric subject)  
 
___________________________________  
Printed Name of Person Conducting the  
Informed Consent Discussion  
 
___________________________________ ___________________  
Signature of Person Conducting the Date (dd/mm/yyyy)  
Informed Consent Discussion  
 
___________________________________  
Printed Name of Witness (if applicable)  
 
___________________________________ ___________________  
Signature of Witness (if applicable) Date (dd/mm/yyyy) 
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Questionnaire 
General Information – The following questions should be filled by the interviewer 
1.1 MODULE 1 
SOCIODEMOGRAPHICS 
  
 
1.2 Hospital ID number  |__|__|__| 
1.3 Date of Interview  
(DD.MM.YYYY) 
  
|__|__| . |__|__| . |__|__|__|__| 
  Day      Month         Year 
1.4 Participant ID  |__|__|__|__|__|__|__| 
1.5 Sex of participant 1 
2 
Male  
Female  
1.6 Name of Study Site 1 
2 
3 
4 
5 
Almaty region 
East Kazakhstan 
North Kazakhstan 
West Kazakhstan 
Kyzylorda  
Start of Interview – The following questions should be asked to the patient 
1.7 When were you born? 
(INT: Enter “99” if day 
and/or month is unknown 
and 9999 if year is 
unknown) 
  
|__|__| . |__|__| . |__|__|__|__| 
  Day     Month          Year 
1.8 How old are you now?  
(Enter “999” for declined to 
answer) 
 |__|__|__| 
Age in years 
1.9 What is your present marital 
status?  
 
1 
2 
3 
4 
5 
6 
7 
Single 
married 
Not married, living with permanent partner 
Separated/divorced 
Widowed 
Declined to answer  
Other (please specify) 
__________________________ 
1.10 Where were you born? 
(country of birth) 
1 Kazakhstan 
2 Kirgistan 
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3 Usbekistan 
4 Other country (please specify): 
__________________________ 
1.11 In which oblast of 
Kazakhstan were you born? 
  
____________________________ 
1.12 
 
In which City/Town/Village 
do you live?  
 
  
____________________________ 
1.13 Since when have you been 
living in this 
City/Town/Village? 
(Enter “999” for declined to 
answer/don’t know) 
1 Always lived in this place 
2 Since    |__|__|__|  Years 
1.14 Have you done any trips 
from your place of residence 
within the last month? 
1 
2 
No 
Yes (please specify where): 
__________________________ 
1.15 Have you done a trip into 
nature? 
1 
2 
No 
Yes (please specify where, when and how 
often): 
__________________________ 
__________________________ 
__________________________ 
__________________________ 
1.16 Have you had contact with 
wild animals?  
 
1 
2 
No 
Yes (please specify): 
____________________________ 
1.17 Have you been biten by 
ticks, mosquitoes, insects or 
wild animals within the last 
month? 
1 
2 
No 
Yes (please specify) 
____________________________ 
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MODULE 2 EDUCATION AND WORK 
2.1 What is your highest 
level of education? 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Still in school (pupil/student) 
Still in college (student) 
Still in academy/institute/university (student) 
Secondary education 
Secondary education unfinished 
Any vocational education 
Vocational education unfinished 
Any higher education 
Higher education unfinished 
Have no formal education 
Declined to answer/Don’t know 
2.2 What is your current 
occupation? 
 
Ful
l-time 
Part-
time 
 
  (Multiple answers 
allowed. For each 
single answer please 
ask If the work is done 
full-time or part-time) 
 
 
 
 
 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 
Pupil/Student (full-time)  
Farmer/Peasant/Farmworker (plants) 
Farmer/Peasant/Farmworker (animal)  
Farmer/Peasant/Farmworker (forestry) 
Keeping the house (housewife) 
Unskilled Labourer 1 
__________________ 
Skilled Labourer 2     
__________________ 
Local or long distance driver  
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6 
7 
8 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
10 
 
11 
 
12 
 
13 
 
14 
Administrative or academic professional 
3 
Businessman/woman 
Nurse/Physician/Clinician/Pharmacist 
Unemployed 
Declined to answer 
Other (please specify) 
______________________________ 
1 please specify 
2 factory worker, mechanic, painter, welder, carpenter, 
dressmaker, technician… 
3 secretary, bank clerk, teacher, pastor, surveyor, lawyer, 
accountant, engineer, labworker, scientist… 
2.3 How long have you 
been working in your 
current occupation? 
(Enter “99” for 
declined to 
answer/don’t know) 
 
       |__|__| 
       Years 
2.4 How often do you 
normally work in the 
gardens and fields? 
(plant cultivation) 
  
1 
2 
3 
45 
Yes, always/daily 
Yes, often 
Yes, occasionally 
No, never 
2.5 Can you read a letter 
or newspaper easily, 
1 
2 
Easily 
With difficulty 
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with difficulty, or not at 
all? 
3 
4 
Not at all 
Declined to answer 
2.6 What is the total cash 
income of your 
household per year?  
1 
2 
 
3 
4 
Low (below 900,000 tenge, 5,000 $ per year) 
Medium (900,000 – 1,800,000 tenge, 5,000 - 
10,000 $ per year) 
High (> 1,800,000 tenge (>10,000 $ per year) 
Decline to answer/do not know 
 
Module 3 LIVING AND HOUSING 
3.1 How many people do 
normally eat together in 
your household? 
(Enter “99” for declined 
to answer/don’t know) 
 
      |__|__| 
     Number 
 
3.2 What type is your 
flat/house? 
 
1 
2 
3 
 
4 
 
Well-equipped city apartment 
Poorly equipped city apartment 
Private well-equipped house 
Poorly equipped house 
Other (please specify): 
_____________________________________ 
 
3.3 Where do you store your 
bulk products (flour, 
sugar, rice, etc…)? 
1 
2 
3 
In bags 
In casks 
Other (please specify) 
 
_____________________________________
_ 
 
3.4 From where do you get 
your water? 
3 
4 
5 
5 
city water pipe 
rural water pipe 
blow well 
river 
 
3.5 Did you drink raw milk 
directly from the animal 
or eat raw milk products 
without pasteurization? 
1 
2 
No 
Yes 
If yes, from which animal? 
_____________________________________
_ 
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MODULE 4: livestock 
4.1 What kind of livestock does 
your household own and 
how many of each 
species?  
(if the real number is 
unknown, please estimate 
– Enter “000” for animal if 
none and “999” for don’t 
know) 
 
 
 
 Cattle               |__|__|__| Number   
Horse               |__|__|__| Number   
Goats               |__|__|__| Number   
Sheep              |__|__|__| Number 
Pigs                 |__|__|__| Number  
Poultry             |__|__|__| Number  
Cats/Dogs       |__|__|__| Number  
other: ________________________________ 
4.2 Did the animals have any 
kind of disease? 
1 Yes 
If yes, which kind of animal?  
________________________________ 
2 No 
4.3 Which symptoms did you 
notice? 
1 
2 
3 
4 
5 
 
6 
Unusual movement 
Respiratory symptoms 
Gastroenterological symptoms 
Lesions 
Others, please specify:  
________________________________ 
Don’t know 
4.4 Did you notice an unusual 
high number of animal 
deaths? 
1 No 
2 Yes 
If yes, which animal?  
_________________________________ 
4.5 Do you have contact with 
died animals? 
1 
2 
No 
Yes 
If yes, which animal?  
_________________________________ 
4.6 How often do you have 
direct contact to the 
 Always/daily Most of 
the times 
Rarely Never 
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following animals?  
(“Contact” means working 
with these animals, milking, 
slaughtering, handling raw 
meat), but NOT eating 
cooked meat 
Cattle?  1 2 3 4 
Horse  1 2 3 4 
Goats?  1 2 3 4 
Sheep  1 2 3 4 
Pigs?  1 2 3 4 
Cats/Dogs  1 2 3 4 
Poultry?  1 2 3 4 
4.7 Do you handle raw meat? 
(slaughtering, butchering, 
preparing for cooking) 
1 
2 
3 
4 
Yes, always 
Yes, most of the times 
Yes, but rarely 
No, never 
4.8 How often do you 
see/notice rats or mice (or 
bat poop) 
1 
2 
3 
4 
Always 
Most of the times 
Rarely 
Never 
4.9 How often do you have to 
kill them in the house? 
1 
2 
3 
4 
Always 
Most of the times 
Rarely 
Never 
4.10 Do you have bird nests in 
the roof? 
  
1 
2 
3 
Yes  
No 
Don’t know 
4.11 Do bats live in your house 
or in trees around your 
house? 
1 
2 
3 
Yes 
No 
Don’t know 
 
MODULE 5: VECTOR HABITAT FACTORS 
5.1 Where is your house 
located, in urban or rural 
1 
2 
Rural area 
Urban area 
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area?  
5.2 What kind of ground is 
around your residence?  
1 
2 
3 
Tarmac 
Sand  
Dirt 
5.3 How does the vegetation 
around your residence look 
like? 
(Multiple answers allowed – 
mark all that apply.) 
 
1 
2 
3 
4 
5 
6 
7 
Dense plantation/forest 
Larger grass fields 
Occasional bush agricultural fields 
Swamp  
Lake 
Forest 
Others (please specify):  
 
5.4 Is there sometimes 
standing water close to 
your residence? 
(Multiple answers allowed) 
 
1 
2 
3 
4 
5 
6 
7 
7 
Yes: 
Puddles after heavy rain 
Containers for collecting water  
Lake 
stream 
Gully in urban area 
No, never 
Don’t know 
5.5 How many months per year 
is that water around your 
residence? 
 
 |__|__| 
Number of month 
 
MODULE 6: CLINICAL SYMPTOMS 
6.1 Beginning of the 
symptoms 
1 
2 
> 5 days ago 
< 5 days ago 
6.2 Please indicate below 
which symptom(s) you 
have: 
1 
2 
3 
Fever 
Headache 
Neck pain (meningism) 
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4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Weakness of muscels or joints 
Muscle pain or recurrent cramps 
Pain on swallowing 
Joint pain 
Stomach/abdominal pain/cramps 
Back pain 
Earache 
Cough 
Difficulties in speaking, hearing or seeing 
Seizures/Epilepsy 
Difficulties in breathing,  
Rapid breathing 
Sore threat 
Congestion of nose 
Enlarged lymph nodes 
Icterus 
6.3 Body temperature 
(ear measurement) 
1 
2 
< 37.5°C 
> 37.5°C 
If body temperature is > 37.5°C, than fill out 6.4 
6.4 Duration of high body 
temperature 
1 
2 
< 3 days 
3 days and more 
6.5 Blood pressure 1 
2 
3 
Normal 
Hypotension 
Hypertension 
6.6 Pulse rate 1 
2 
3 
< 80 
80 – 100 
> 100 
6.7 Skin conditions 1 
2 
3 
4 
Exanthema 
Ulceration 
Edema 
Others (please specify) 
__________________________________ 
6.8 Stool 1 
2 
3 
4 
Diarrhoea 
Blood in stool 
Bright stool 
Others (please specify) 
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__________________________________ 
6.9 Urine 1 
2 
3 
4 
5 
Blood in urine 
Pain on urinating 
Dark urine 
Low urine volume 
Others (please specify) 
__________________________________ 
6.10 Medications 1 
2 
3 
4 
Antipyretics 
Antirheumatics 
Antibiotics 
Others (please specify) 
___________________________________ 
6.11 Duration of therapy  __ Days  
6.12 Similar illnesses in the 
family or in the 
surrounding 
1 
2 
Yes 
No 
 
 
 
 
 
 
 
 
 
 
